[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4790
1. Coche D, Bergues B, Harrivel V, Guillaume N: [Biphenotypic acute leukaemia with Burkitt-like cytology]. Ann Biol Clin (Paris); 2009 Jul-Aug;67(4):437-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biphenotypic acute leukaemia with Burkitt-like cytology].
  • [Transliterated title] Leucémie aiguë biphénotypique avec aspect cytologique de type Burkitt.
  • Biphenotypic acute leukaemia (BAL) represents about 5% of adult acute leukaemia.
  • Based on a previously described scoring system, the European Group for Immunologic Classification of Leukaemia (EGIL) proposed a set of diagnostic criteria for BAL.
  • Here, we report the case of a BAL with Burkitt-like cytology, corresponding to "the acute lymphoblastic leukaemia, Burkitt type" L3 for the FAB classification.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / genetics
  • [MeSH-minor] Adult. Blast Crisis / pathology. Burkitt Lymphoma / pathology. Flow Cytometry / methods. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19654084.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Rajić Z, Colović N, Sretenović M, Plecić M, Janković S, Bakrac M, Colović M: [Hepatosplenic candidiasis in acute leukaemia patients]. Srp Arh Celok Lek; 2008 Jul-Aug;136(7-8):414-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatosplenic candidiasis in acute leukaemia patients].
  • INTRODUCTION: Hepatosplenic candidiasis is a disseminated invasive fungal infection that may affects patients with acute leukaemia.
  • CASE OUTLINE: The authors present three patients, two women and one men, aged 23, 26 and 33 years, with acute leukaemia; one with acute myeloblastic and two with acute lymphoblastic leukaemia who developed hepatosplenic candidiasis.
  • The diagnosis was based on prolonged fever, elevated serum bilirubin and alkaline phosphatase, as well as characteristic lesions on computed tomography, nuclear magnetic resonance and ultrasonographic findings and positive blood culture in one patient.
  • Two patients died due to progression of leukaemia.
  • CONCLUSION: If leukaemia patient in remission after chemotherapy develops a prolonged fever of unknown origin, hepatosplenic candidiasis has to be considered and all efforts should be done to diagnose it.
  • The diagnosis is based on clinical presentation and imaging techniques.
  • [MeSH-major] Candidiasis / complications. Immunocompromised Host. Leukemia, Myeloid, Acute / complications. Liver Diseases / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Splenic Diseases / complications


3. Loh AH, Chui CH: Port-A-Cath insertions in acute leukaemia and childhood malignancies. Asian J Surg; 2007 Jul;30(3):193-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port-A-Cath insertions in acute leukaemia and childhood malignancies.
  • Incidence of catheter-related bloodstream infections (CRBSIs), other complications and CRBSI-related port removals were analysed for cases with acute leukaemia versus other malignancies.
  • While mean preoperative platelet count was 125.34 x 10(9)/L in children with acute leukaemia and 392.11 x 10(9)/L in those with other malignancies (p < 0.01), the incidence of all complications were similar between both subgroups.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638639.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Schalk E, Mohren M, Jentsch-Ullrich K, Dombrowski F, Franke A, Koenigsmann M: Zygomycoses in patients with acute leukaemia. Ann Hematol; 2006 May;85(5):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zygomycoses in patients with acute leukaemia.
  • The high mortality rate is due to a high failure rate of both intravital diagnosis and treatment.
  • Exact diagnosis requires microscopic examination and proof by culture.
  • We report four recent cases of zygomycosis among 89 patients with intensively treated acute leukaemia at our institution.
  • Three cases were breakthrough infections since the patients were under voriconazole treatment prior to diagnosis of zygomycosis.
  • Only one patient had premortal diagnosis (paranasal sinus infection) and showed clinical response with amphotericin B and surgical debridement.
  • A review of the literature of these emerging fungal infections is given and is focused on patients with acute leukaemia.
  • [MeSH-major] Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Immunocompromised Host. Leukemia. Zygomycosis / diagnosis. Zygomycosis / therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523312.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  • [Number-of-references] 39
  •  go-up   go-down


5. Menegaux F, Baruchel A, Bertrand Y, Lescoeur B, Leverger G, Nelken B, Sommelet D, Hémon D, Clavel J: Household exposure to pesticides and risk of childhood acute leukaemia. Occup Environ Med; 2006 Feb;63(2):131-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Household exposure to pesticides and risk of childhood acute leukaemia.
  • OBJECTIVES: To investigate the relation between childhood acute leukaemia and household exposure to pesticides.
  • METHODS: The study included 280 incident cases of acute leukaemia and 288 controls frequency matched on gender, age, hospital, and ethnic origin.
  • Odds ratios were estimated using unconditional regression models including the stratification variables parental socioeconomic status and housing characteristics.
  • RESULTS: Acute leukaemia was observed to be significantly associated with maternal home insecticide use during pregnancy (OR = 1.8, 95% CI 1.2 to 2.8) and during childhood (OR = 1.7, 95% CI 1.1 to 2.4), with garden insecticide use (OR = 2.4, 95% CI 1.3 to 4.3), and fungicide use (OR = 2.5, 95% CI 1.0 to 6.2) during childhood.
  • Insecticidal shampoo treatment of pediculosis was also associated with childhood acute leukaemia (OR = 1.9, 95% CI 1.2 to 3.3).
  • CONCLUSION: The results reported herein support the hypothesis that various types of insecticide exposure may be a risk factor for childhood acute leukaemia.
  • [MeSH-major] Leukemia / chemically induced. Pesticides / toxicity
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Environmental Exposure / adverse effects. Epidemiologic Methods. Female. Humans. Infant. Infant, Newborn. Insecticides / toxicity. Lice Infestations / drug therapy. Male. Maternal Exposure / adverse effects. Paternal Exposure / adverse effects. Pregnancy. Prenatal Exposure Delayed Effects. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Apr 1;151(7):639-46; discussion 647-50 [10752791.001]
  • [Cites] Epidemiology. 2005 Jan;16(1):93-100 [15613951.001]
  • [Cites] Environ Health Perspect. 2002 Mar;110(3):319-24 [11882484.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Eur J Pediatr. 2002 Apr;161(4):235-7 [12014398.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):955-60 [12204832.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):60-3 [12540505.001]
  • [Cites] Eur J Cancer Prev. 2004 Apr;13(2):97-103 [15100575.001]
  • [Cites] Occup Environ Med. 2004 Sep;61(9):773-8 [15317919.001]
  • [Cites] J Natl Cancer Inst. 1987 Jul;79(1):39-46 [3474448.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):4030-7 [2736544.001]
  • [Cites] Am J Public Health. 1995 Feb;85(2):249-52 [7856787.001]
  • [Cites] Eur J Cancer. 1996 Oct;32A(11):1943-8 [8943679.001]
  • [Cites] Environ Health Perspect. 1997 Oct;105(10):1068-77 [9349828.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Epidemiology. 1999 Sep;10(5):481-7 [10468419.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):935-41 [11808713.001]
  • (PMID = 16421392.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insecticides; 0 / Pesticides
  • [Other-IDs] NLM/ HALMS85342; NLM/ PMC2078075
  •  go-up   go-down


6. Weight is a risk factor for treatment mortality in AML. Nurs Stand; 2005 Feb 16;19(23):10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Underweight or overweight children with acute myeloid leukaemia (AML) are more likely to succumb to treatment-related complications than their normal weight counterparts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28091019.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A: Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer; 2006 Jan 30;94(2):200-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of venous thromboembolism in patients with acute leukaemia.
  • Patients with malignancies have an increased risk for venous thromboembolisms (VTE), but data on patients with acute leukaemia are very limited so far.
  • We found VTE in 12% of 455 patients with acute leukaemia, half of which occurred in association with central venous catheters, with equal risk of ALL and AML.
  • [MeSH-major] Leukemia / complications. Venous Thrombosis / epidemiology. Venous Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Thromb Haemost. 2005 Sep;3(9):1985-92 [16102104.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):43-52 [12508268.001]
  • [Cites] Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21 [12814981.001]
  • [Cites] Leuk Lymphoma. 2003 Sep;44(9):1495-501 [14565650.001]
  • [Cites] Arch Intern Med. 2004 Jan 26;164(2):190-4 [14744843.001]
  • [Cites] J Thromb Thrombolysis. 2003 Aug-Oct;16(1-2):21-31 [14760208.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):92-5 [15226761.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1128-33 [1528208.001]
  • [Cites] N Engl J Med. 1998 Apr 23;338(17):1169-73 [9554856.001]
  • [Cites] Lancet. 1998 Apr 11;351(9109):1077-80 [9660575.001]
  • [Cites] Thromb Res. 2005;115(1-2):59-64 [15567454.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1349-51 [15798767.001]
  • [Cites] Thromb Res. 2005;116(2):109-14 [15907524.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):811-7 [15953009.001]
  • [Cites] Arch Intern Med. 2005 Aug 8-22;165(15):1782-7 [16087828.001]
  • [Cites] Thromb Haemost. 2002 Apr;87(4):575-9 [12008937.001]
  • (PMID = 16421591.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361116
  •  go-up   go-down


8. Singh H, Prasad BN, Jagdish, Batra A: Hyperleukocytosis associated pulmonary leukostasis in acute leukaemia. J Assoc Physicians India; 2006 May;54:405-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis associated pulmonary leukostasis in acute leukaemia.
  • Leukostasis is a fatal complication in granulocytic leukaemia.
  • In the lung, the clinical presentation simulates infections and haemorrhagic complications of acute leukaemia.
  • [MeSH-major] Leukemia / complications. Leukocytosis / etiology. Leukostasis / etiology. Lung Diseases / etiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909741.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. Racay P, Hatok J, Hudecek J, Chudej J, Jurecekova J, Dobrota D: Transcription of genes of p53-dependent apoptosis in acute leukaemia. Int J Mol Med; 2008 Dec;22(6):833-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription of genes of p53-dependent apoptosis in acute leukaemia.
  • Tumour suppressor protein p53 prevents cancer development through various mechanisms, including the induction of apoptosis.
  • We demonstrated that acute leukaemia, myeloblastic (AML) and lymphoblastic (ALL), is associated with significantly elevated levels of p53 and Bax mRNA in leukaemic cells.
  • Altered alternative processing of Bcl-x and myeloid cell leukaemia-1 (MCL1) primary transcripts were observed in the case of AML and AML and ALL, respectively.
  • In addition, transcription of hsp70.1 and Bcl-2 producing anti-apoptotic proteins was not affected in acute leukaemia.
  • [MeSH-major] Apoptosis. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription, Genetic. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Actins / genetics. Actins / metabolism. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Glyceraldehyde-3-Phosphate Dehydrogenases / metabolism. HSP70 Heat-Shock Proteins / genetics. HSP70 Heat-Shock Proteins / metabolism. Humans. Leukocytes, Mononuclear / metabolism. Myeloid Cell Leukemia Sequence 1 Protein. Polymorphism, Single-Stranded Conformational. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. bcl-2-Associated X Protein / genetics. bcl-2-Associated X Protein / metabolism. bcl-X Protein / genetics. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020783.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / BCL2L1 protein, human; 0 / HSP70 Heat-Shock Proteins; 0 / MCL1 protein, human; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


10. Gorschlüter M, Schmitz V, Mey U, Hahn-Ast C, Schmidt-Wolf IG, Sauerbruch T: Endoscopy in patients with acute leukaemia after intensive chemotherapy. Leuk Res; 2008 Oct;32(10):1510-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopy in patients with acute leukaemia after intensive chemotherapy.
  • Gastrointestinal complications are important causes of morbidity and mortality in patients with acute leukaemia.
  • [MeSH-major] Cholangiopancreatography, Endoscopic Retrograde. Endoscopy, Gastrointestinal. Gastrointestinal Diseases / epidemiology. Leukemia / complications. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Gastrointestinal Hemorrhage / epidemiology. Gastrointestinal Hemorrhage / etiology. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18495243.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Duncan C, Roddie H: Dendritic cell vaccines in acute leukaemia. Best Pract Res Clin Haematol; 2008 Sep;21(3):521-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell vaccines in acute leukaemia.
  • There is a need for novel treatment for acute leukaemia as relapse rates remain unacceptably high.
  • Immunotherapy aims to stimulate the patient's immune responses to recognize and destroy leukaemia cells whilst activating immune memory.
  • The qualities of the most potent professional antigen-presenting cell, the dendritic cell (DC), can be used to stimulate leukaemia-specific cytotoxic T cells.
  • DCs can be loaded with leukaemia antigens, or leukaemia blasts can be modified to express DC-like properties for use in vaccine therapy.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Dendritic Cells / immunology. Leukemia / immunology
  • [MeSH-minor] Acute Disease. Adoptive Transfer / methods. Clinical Trials as Topic. Humans. Jurkat Cells. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy. T-Lymphocytes / immunology. T-Lymphocytes / transplantation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790453.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 111
  •  go-up   go-down


12. Turial S, Karabul N, Gutjahr P, Engel V, Bierschock S, Schier F: Ovarian tumours: late extramedullary recurrence of acute leukaemia. Eur J Pediatr Surg; 2009 Jun;19(3):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumours: late extramedullary recurrence of acute leukaemia.
  • OBJECTIVE: Isolated extramedullary relapse, especially ovarian recurrence, of acute leukaemia is rare.
  • MATERIALS AND METHODS: Over a 20-year period we observed two girls with ovarian relapse of acute lymphoblastic leukaemia (ALL) in over 300 treated children for ALL.
  • CONCLUSION: Because we experienced favourable results with laparoscopic biopsy in our patients, we are of the opinion that laparoscopy-assisted biopsies are well suited for the management of intra-abdominal tumours in systemic malignant disease.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212934.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S, Raina V, Thulkar S: Febrile neutropenia during acute myeloid leukemia therapy: Single institution experience from a developing country. J Clin Oncol; 2009 May 20;27(15_suppl):e18000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile neutropenia during acute myeloid leukemia therapy: Single institution experience from a developing country.
  • : e18000 Background: Febrile neutropenia poses a major challenge during treatment of acute myeloid leukaemia (AML).
  • RESULTS: 402 febrile episodes including 363 episodes of febrile neutropenia (180 in induction, 183 in consolidation) and 39 non-neutropenic episodes (18 in induction, 21 in consolidation) occurred.
  • Prompt and proper institution of antibiotics and antifungals besides considering alternative diagnosis peculiar to the region (e.g. tuberculosis, malaria) may aid in better management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Veuillen C, Gravis G, Marcy M, Walz J, Bladou F, Salem N, Brunelle S, Olive D: Alterations of natural killer cells in metastatic prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16131
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, our group have reported that patients with acute myeloid leukaemia have defective interactions receptor -ligand in NK cells due to a decreasing expression of Natural Cytotoxicity Receptors and it could be used as a evasion mechanism by leukaemia cells.
  • Is it hormonal therapy or extension of the disease that is responsible of NK cells alterations?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963371.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Pratz KW, Cho E, Karp J, Levis M, Zhao M, Rudek M, Wright J, Smith BD: Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol; 2009 May 20;27(15_suppl):7065
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias.
  • Based on preclinical activity in FLT3 mutant AML, sorafenib was studied in refractory acute leukemia.
  • METHODS: The primary objective was to determine the safety and tolerability of sorafenib in refractory acute leukemias.
  • No patients met criteria for complete or partial response, but 11 of 15 (73%) patients experienced stable disease as best response, with 6 showing a reduction in bone marrow blasts after only one cycle, half of who experienced a >50% reduction in bone marrow blasts.
  • Interestingly, 2 pts with FLT3-ITD mutations both showed marrow blast response (1 pt >50%).
  • Clinical activity as a single agent was limited to transient reductions in bone marrow blast counts and dose escalation was limited due to toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Bloomfield CD: Importance of genetic heterogeneity in curing adult acute leukemia (AL). J Clin Oncol; 2009 May 20;27(15_suppl):s1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of genetic heterogeneity in curing adult acute leukemia (AL).
  • Publication of the French-American-British classification 34 years ago resulted in acceptance that morphology and cytochemistry separated AL into two different diseases, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), that required separate treatment.
  • The most striking example of increased curability of AL is acute promyelocytic leukemia, in which targeted therapy combined with chemotherapy has increased survival from a 2-week median to an 80% cure rate.
  • Recognition of increased sensitivity of a genetic subtype of AML to high-dose cytarabine (HiDAC) has increased the cure rate of core-binding factor (CBF) AML from <10%-25% to 55%-60%.
  • Among adult de novo AML 40%-45% are cytogenetically normal (CN); the striking molecular heterogeneity of CN-AML is now being recognized and promises to allow individualized approaches that improve substantially upon the current cure rate of 40%.
  • New approaches to studying the leukemia genome and epigenome should improve our understanding of AL heterogeneity, identify new therapeutic targets, and allow the cure of most patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962366.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Maternal alcohol intake linked to leukaemia in childhood. Nurs Stand; 2007 Aug 29;21(51):17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal alcohol intake linked to leukaemia in childhood.
  • : More than one alcoholic drink a day during pregnancy might be associated with the development of acute lymphoblastic leukaemia in the subsequent child.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001545.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Plunkett W, Thomas DA, O'Brien SM, Federl S, Giles FJ, Nicol SJ, Gill J, Zhao L, Ravandi F, Kantarjian H: Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7068
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia.
  • The purpose of this phase I trial was to define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of pemetrexed given with vitamin supplementation to patients with relapsed or refractory leukemia.
  • METHODS: Patients ≥15 years of age were enrolled with relapsed or refractory leukemia, Eastern Cooperative Oncology Group performance status ≤2, adequate renal and hepatic function, and life expectancy of ≥6 weeks.
  • RESULTS: Twenty-two patients entered the trial; median age was 50 years (range: 18-75); 15 patients had acute myeloid leukemia and 7 patients had acute lymphocytic leukemia (ALL).
  • Two patients died during the study due to disease progression and 1 patient discontinued due to a subdural hematoma of unknown cause.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Nikolic NM, Tomasevic Z, Jelic S: Secondary malignancies developing during metastatic breast cancer treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e12020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e12020 Background: Secondary malignancies (SM) developing during metastatic breast cancer (MBC) are obviously more complicated for diagnosis, potential surgery and for further MBC treatment.
  • Patients with contra-lateral BC and acute leukemia were excluded.
  • CONCLUSIONS: According to our experience, SM develops more frequently in MBC than in non MBC patients, representing 60% (30/50 patients) of all SM in BC patients; 46.6% (14/30) of SM diagnosed during MBC could be surgically resected, and does not influence further MBC treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Rangarajan B, Prabhash K, Nair R, Menon H, Jain P, Kannan S, Jeevangi NK, Bagal B, Parikh PM, Kurkure PA: Rater. J Clin Oncol; 2009 May 20;27(15_suppl):e20678
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria were diagnosis of hematolymphoid malignancy, neutropenic febrile episode secondary to chemotherapy or during induction therapy of acute leukemia and more than 18 years of age All patients were risk stratified, hospitalized and treated with broad-spectrum, empiric, intravenous antibiotic therapy until recovery or outcome of the event.
  • We subsequently analyzed the subset of Acute Myeloid Leukemia (AML) patients as they were the majority comprising of 62/81 episodes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961676.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Mayer F, Weidmann J, Federmann B, Schwarz S, Hartmann JT, Kanz L, Bethge W: Clinical impact and follow-up of taste disturbances following myeloablative or nonmyeloablative chemotherapy and stem cell transplantation. J Clin Oncol; 2009 May 20;27(15_suppl):e20609
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact and follow-up of taste disturbances following myeloablative or nonmyeloablative chemotherapy and stem cell transplantation.
  • : e20609 Background: Stem cell transplantation (SCT) after myeloablative (MA) or non-myeloablative (NMA) chemotherapy is a successful treatment option for a variety of diseases.
  • Indications for SCT included acute leukemia (n=38), myeloproliferative disease (n=20), lymphoma (n=13), and others (n=29).
  • 75% of pts reported moderate to severe changes in taste perception on a semiquantitative visual analogue scale during the acute phase of SCT with no differences between the three groups (73%, 79%, 75%).
  • The lower incidence of persiting changes in taste perception after autologous SCT might be attributed to the absence of graft versus host disease or the dispensability of immunosuppression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961552.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Pigazzi M, Manara E, Baron E, Beghin A, Basso G: The inducible cyclic adenosine 3',5'-monophosphate early repressor (ICER) enhances drug sensitivity in acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e22045
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inducible cyclic adenosine 3',5'-monophosphate early repressor (ICER) enhances drug sensitivity in acute myeloid leukemia.
  • CREB was previously demonstrated to be overexpressed in acute leukemia, whereas ICER was found rapidly degradated being unable to control gene transcription.
  • ICER exogenous expression was demonstrated to repress CREB targets preventing leukemia progression.
  • We hypothesized that ICER restoration deserves a special consideration for playing a role in CREB oncogenic feature and in modeling leukemic cell phenotype.
  • We monitored transcription and translation of a series of genes involved in different pathways by quantitative gene expression and western blot analysis.
  • We investigate ICER's role in cell death after treatment with chemotherapic drugs.
  • RESULTS: We revealed that ICER was able to control gene expression in leukemia, principally of genes involved in cell death and survival.
  • Cell cycle analyses revealed a block in G2 phase, a lowered cell proliferation and clonogenic potential with respect to HL60 treated at the same conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963227.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Rao SR, Hassett M, Schwartz JH, Maloney B, Jacobson JO: Admissions for chemotherapy-related serious adverse effects (CR-SAEs) and rates of mortality among community cancer center patients. J Clin Oncol; 2009 May 20;27(15_suppl):6571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a prospective cohort study of adult cancer patients (excluding acute leukemia and stem cell transplant patients) admitted to a community hospital January 2003-December 2006.
  • We identified the type of SAE, outcome of each admission, time form chemotherapy to admission and from admission to discharge/death, and the disease and treatment characteristics of each patient.
  • The average time from chemotherapy to admission was shorter for fatal vs. non-fatal admissions (3.6 vs. 7.7 days; p<.01).
  • CONCLUSIONS: Fatalities during admissions for CR-SAE's in a community cancer center are relatively uncommon and are not associated with age or type of SAE/cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963798.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Duhoux F, Libouton J, Bahloula K, Ameye G, Poirel HA: Identification by FISH of 4 novel partner loci of PRDM16 in myeloid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):11037
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11037 Background: PRDM16 is a gene located on 1p36.32 that encodes for a zinc finger transcription factor and contains an N-terminal PR domain.
  • It has been shown to be involved in the reciprocal translocation t(1;3)(p36;q21) and more rarely the t(1;21)(p36;q22) which both occur in myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML).
  • These translocations result in the overexpression of a truncated version of the PRDM16 protein that lacks the PR domain.
  • METHODS: We studied 35 myeloid malignancies, 12 lymphoid malignancies and 3 undifferentiated acute leukemias with 1p36 abnormalities by fluorescent in situ hybridization (FISH) with a bacterial artificial chromosomes (BAC) contig containing 50 BAC probes on 1p36.
  • We identified the respective candidate partner loci : TEL/ETV6, IKZF1, CDH4 and a non-coding unknown sequence.
  • Interestingly, the shortest isoform of MDS/EVI-1, lacking the PR domain, is supposed to have an oncogenic effect due to its translocation-induced upregulation in AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • Twenty-one pts had pre-B ALL, 5 pts pre-T/T ALL, 1 pt mature B ALL, and 3 pts biphenotypic acute leukemias.
  • One (20%) pt in cohort 1 and 9 (36%) in cohort 2 experienced DLTs (≥ grade 3) including transaminase elevations, diarrhea, hyperbilirubinemia, and (1 pt each) elevation of creatinine/renal failure, lipase elevation, rash, nausea/vomiting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Mohty M, Balere M, Socie G, Milpied N, Ifrah N, Harousseau JL, Michallet M, Blaise D, Esperou H, Yakoub-Agha I, SFGM-TC: Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD). J Clin Oncol; 2009 May 20;27(15_suppl):7025
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD).
  • : 7025 Here, we report the results of a multicenter retrospective study analyzing the effect of ATG, incorporated within the MAC regimen for MUD-transplants in leukemic patients.
  • The purpose of the study was to compare the incidence and severity of acute and chronic GVHD as well as overall outcome.
  • 171 adult patients with acute leukemia and MDS, for whom detailed allelic HLA typing (4 digits) was available, were included.
  • With a median follow-up of 30.3 (range, 2.6-68.1) months, grade 0-1 and 2-4 acute GVHD occurred in 74 (46%) and 88 patients (54%) respectively, with grade 3-4 acute GVHD being significantly lower in the ATG group (18% vs. 32%; p = 0.04).
  • In multivariate analysis, an HLA allelic mismatch and the non-use of ATG were associated with an increased risk of grade 3-4 acute GVHD (RR = 2.80, 95% CI, 1.5-5.3, p = 0.001; and RR = 2.4, 95% CI, 1.1-5.0, p = 0.02 respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961398.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Lopez-Enriquez AT: Acute promielocytic leukemia: 14 years experience at the University Hospital, San Juan, Puerto Rico. J Clin Oncol; 2009 May 20;27(15_suppl):e18006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promielocytic leukemia: 14 years experience at the University Hospital, San Juan, Puerto Rico.
  • : e18006 Background: Acute promielocytic leukemias (APL) are a unique example in carcinogenesis, of maturation arrest at the promielocytic stage, associated with a chromosomal reciprocal translocation of a portion of chromosome 15 and 17 with the formation of fusion proteins between the PML gene and the alpha-retinoic acid receptor site.
  • METHODS: Since 1994 when transretinoic acid (ATRA) became available to us, we developed a protocol incorporating this drug to the standard regime of induction chemotherapy for acute leukemias used in our institution of 7 days of continuous infusion of cytosine arabinoside (Ara-C) and three days of daunorubicine (7+3), starting the ATRA on day 14 at 45 mg/m2 and continued daily for 120 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963993.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Tagawa ST, Parmar S, Pena J, Petrillo K, Matulich D, Selzer J, Vallabhajosula S, Goldsmith SJ, Bander NH, Nanus DM: Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases of marrow damage, including myelodysplasia and acute leukemia have been reported with the RIT most used to date (that targeting CD20 in Non- Hodgkin's lymphoma), though no statistically significant association exists.
  • Specific searches for subsequent myelodysplasia and/or leukemia were performed.
  • No cases of post-RIT myelodysplasia and/or leukemia were discovered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Ghavamzadeh A, Allahyari A, Alimoghaddam K, Karimi A, Shamshiri A, Abolhasani R, Manookian A, Asadi M, Khatami F: Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7042
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders.
  • : 7042 Background: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias.
  • The aim of this study was to compare the time of engraftment and mortality rate and cost of neutropenic treatment in outpatient versus inpatient autologous stem cell transplantation (SCT).
  • They received conditioning regimen (CEAM for NHL and HL, busulfan and etoposide for AML) and stem cell infusion in hospital.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Kadia TM, Faderl S, Estrov Z, Konopleva M, George S, Lee W, Puzanov I, Chen A, Kantarjian H, Ravandi F: Final results of phase I and pharmacokinetic study of SJG-136 administered on a daily x 5 schedule. J Clin Oncol; 2009 May 20;27(15_suppl):e13506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report the results of a CTEP-sponsored phase I trial of SJG-136 administered on a daily x 5 schedule in pts with relapsed or refractory (R/R) leukemias.
  • METHODS: Previously treated pts with R/R acute leukemias (AML, ALL, high risk MDS, CML blast phase) or R/R CLL with adequate organ function and ECOG performance status of ≤ 2 were eligible for the study.
  • Other manifestations of vascular leak including grade I, II hypoalbuminemia, edema, and pleural effusions were seen in a number of patients starting at dose level 24 mcg/m<sup>2</sup> and above.
  • Other non-dose limiting toxicities included nausea, dyspnea, fatigue, bloating, and insomnia.
  • One pt had a PR, 8 pts had stable disease, and 6 had progression.
  • CONCLUSIONS: SJG-136 is safe and active in patients with advanced leukemias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Köhler K, Regner A, Koenigsmann M, Franke A, Frommer J: [Illness perceptions of patients suffering from acute leukaemia one week after diagnosis]. Z Psychosom Med Psychother; 2005;51(4):388-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Illness perceptions of patients suffering from acute leukaemia one week after diagnosis].
  • OBJECTIVES: To investigate illness perceptions, treatment expectations, and treatment experiences of patients suffering from acute leukaemia in the initial stage of their disease.
  • METHODS: In the first week of treatment we interviewed twelve patients with acute leukaemia using a detailed semi-structured interview guide.
  • [MeSH-major] Leukemia, Myeloid, Acute / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Sick Role

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402336.001).
  • [ISSN] 1438-3608
  • [Journal-full-title] Zeitschrift für Psychosomatische Medizin und Psychotherapie
  • [ISO-abbreviation] Z Psychosom Med Psychother
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Kaćanski N, Konstantinidis N, Kolarović J, Slavković B, Vujić D: [Biphenotypic acute leukaemia: case reports of two paediatric patients]. Med Pregl; 2010 Nov-Dec;63(11-12):867-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biphenotypic acute leukaemia: case reports of two paediatric patients].
  • INTRODUCTION: Biphenotypic acute leukaemia is an uncommon type of leukaemia whose blasts co-express myeloid and B-or T-lymphoid antigens.
  • CASE REPORT: We describe two cases of paediatric patients with biphenotypic acute leukaemia.
  • A four-year-old female patient was found to have myeloid and B-lymphoid associated antigens in the same blast cells.
  • Cytogenetic analysis showed a Philadelphia (Ph) positivity t (9;22) (q34;q1l1 with rearrangements of M.bcr-Abl (p210).
  • She was treated with combined acute myeloid leukaemia/acute lymphoblastic leukaemia induction therapy followed by autologous stem cell transplantation.
  • The patient died due to the complications of stem cell transplantation procedure.
  • Another patient was a 20-month-old girl with myeloid and T-lymphoid associated antigens in the blast cells and with normal karyotype.
  • She received acute myeloid leukaemia induction therapy.
  • DISCUSSION: Immunophenotype is essential to establish the diagnosis of biphenotypic acute leukaemia according to the scoring system adopted by the European Group of Immunological Classification of Leukaemia.
  • There is no agreement about uniformity in treatment for the patients with this type of leukaemia.
  • Biphenotypic acute leukaemia is a high risk leukaemia which requires a more intensive treatment.
  • CONCLUSION: Therapy for every patient with biphenotypic acute leukaemia should depend on their immunophenotype and gene rearrangement profiles.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / diagnosis. Leukemia, Biphenotypic, Acute / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21553470.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


33. Yang Y, Jin XM, Yan CH, Tian Y, Tang JY, Shen XM: Urinary level of nickel and acute leukaemia in Chinese children. Toxicol Ind Health; 2008 Oct;24(9):603-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary level of nickel and acute leukaemia in Chinese children.
  • The 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidized nucleoside of DNA, not only is a widely used biomarker for the measurement of endogenous oxidative DNA damage but might also be a risk factor for many diseases including cancer.
  • However, few studies on urinary 8-OHdG and metals have been conducted in children with acute leukemia.
  • In the present study, urinary Ni and 8-OHdG were examined in 116 children with acute leukaemia (94 acute lymphoid leukaemia [ALL] and 22 acute myeloid leukaemia [AML]) and 51 healthy child controls.
  • Our result showed that urinary Ni in acute leukaemia patients (ALL: 68.40 +/- 133.98, AML: 41.48 +/- 76.31 ng/mg creatinine) was significantly higher than that in controls (62.47 +/- 124.90 vs 17.63 +/- 46.17 ng/mg creatinine, P < 0.05).
  • Moreover, urinary 8-OHdG and urinary Ni showed a weak but significant association with increased risk of childhood leukaemia.
  • The present study suggests that Ni may be an etiologic factor for childhood acute leukaemia by oxidative DNA damage.
  • [MeSH-major] Deoxyguanosine / analogs & derivatives. Leukemia, Myeloid, Acute / urine. Nickel / urine. Precursor Cell Lymphoblastic Leukemia-Lymphoma / urine

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106127.001).
  • [ISSN] 0748-2337
  • [Journal-full-title] Toxicology and industrial health
  • [ISO-abbreviation] Toxicol Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Metals, Heavy; 0 / Metals, Light; 7OV03QG267 / Nickel; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


34. Rowe JM: Graft-versus-disease effect following allogeneic transplantation for acute leukaemia. Best Pract Res Clin Haematol; 2008 Sep;21(3):485-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-disease effect following allogeneic transplantation for acute leukaemia.
  • The graft-versus-leukaemia effect is one of the most important biological effects to influence outcome in patients with acute leukaemia.
  • The recognition of this modality over the past three decades has led to far-reaching changes in the concept and conduct of allogeneic transplantation in acute myeloid leukaemia, and in the infusion of donor lymphocytes as a therapeutic modality.
  • Despite these conceptual advances, there is a considerable need for more structured prospective studies to optimally define the role of reduced-intensity transplantation in both acute myeloid and acute lymphoblastic leukaemia.
  • [MeSH-major] Graft vs Host Disease / immunology. Leukemia / immunology. Leukemia, Myeloid, Acute / immunology. Stem Cell Transplantation / adverse effects. Transplantation, Homologous / immunology
  • [MeSH-minor] Bone Marrow Transplantation / adverse effects. Bone Marrow Transplantation / mortality. Graft vs Leukemia Effect / immunology. Hematopoietic Stem Cells / immunology. Humans


35. Bitner-Glindzicz M, Osei-Lah V, Colvin I, Sirimanna T, Lucas D, Mac Ardle B, Webb D, Shankar A, Kingston J, Jenkins L, Rahman S: Aminoglycoside-induced deafness during treatment of acute leukaemia. Arch Dis Child; 2010 Feb;95(2):153-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminoglycoside-induced deafness during treatment of acute leukaemia.
  • Three unrelated children from ethnically diverse backgrounds who were treated for acute leukaemia became profoundly and irreversibly deaf during treatment.
  • Children diagnosed with acute leukaemia should be tested for this mutation at diagnosis, and alternative antibiotics chosen for the treatment of sepsis.
  • [MeSH-major] Aminoglycosides / adverse effects. Anti-Bacterial Agents / adverse effects. Deafness / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child, Preschool. DNA, Mitochondrial / genetics. Female. Genetic Predisposition to Disease. Humans. Male. Mutation. Opportunistic Infections / drug therapy. Pedigree


36. Meenaghan T, Dowling M: Treatment for acute leukaemia: elderly patients' lived experiences. Br J Nurs; 2010 Jan 14-27;19(1):52-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for acute leukaemia: elderly patients' lived experiences.
  • AIM: The aim of this study was to explore the lived experiences of elderly patients with acute leukaemia receiving chemotherapy.
  • METHOD: Seven elderly patients were interviewed and van Manen's approach to data analysis was used in interpreting the participants' interview transcripts.
  • FINDINGS: Three main themes were interpreted from the study participants' narratives: emotions experienced upon diagnosis; the need of support from family, friends, and healthcare professionals; and the importance of information.
  • CONCLUSION: Although some of the findings are similar to those of previous studies examining patients with other cancers, this is the first known study to examine the lived experience of elderly patients receiving chemotherapy for acute leukaemia.
  • All participants experienced shock and fear at diagnosis.
  • With good support from family, friends and healthcare professionals, participants revealed that they learnt to cope with the diagnosis and its treatments.
  • [MeSH-major] Adaptation, Psychological. Leukemia / psychology
  • [MeSH-minor] Acute Disease. Aged. Emotions. Female. Great Britain. Humans. Male. Social Support

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20081714.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Mosor M, Ziółkowska I, Januszkiewicz-Lewandowska D, Nowak J: Polymorphisms and haplotypes of the NBS1 gene in childhood acute leukaemia. Eur J Cancer; 2008 Oct;44(15):2226-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms and haplotypes of the NBS1 gene in childhood acute leukaemia.
  • This study verified whether polymorphisms of the NBS1 gene may influence susceptibility to the development of childhood acute leukaemia.
  • We genotyped six polymorphisms of the NBS1 gene in 157 children with acute leukaemia and 275 controls.
  • The TT genotype of c.2071-30A>T polymorphism was higher in leukaemia patients than in controls.
  • Genotyping data from the six polymorphic loci in NBS1 in leukaemia patients and controls were used to impute haplotypes.
  • Two of the evaluated haplotypes were associated with significantly increased leukaemia risk (P=0.0038 and P<0.0001).
  • Our results suggest that some specific haplotypes of the NBS1 gene may be associated with childhood leukaemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. Leukemia / genetics. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Polymorphism, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Gene Frequency. Genetic Predisposition to Disease. Genotype. Haplotypes. Humans. Infant

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691878.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / NBN protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


38. McGrattan P, Campbell S, Cuthbert R, Jones FG, McMullin MF, Humphreys M: Integration of conventional cytogenetics, comparative genomic hybridisation and interphase fluorescence in situ hybridisation for the detection of genomic rearrangements in acute leukaemia. J Clin Pathol; 2008 Aug;61(8):903-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of conventional cytogenetics, comparative genomic hybridisation and interphase fluorescence in situ hybridisation for the detection of genomic rearrangements in acute leukaemia.
  • AIMS: To screen for genomic imbalances in patients with acute leukaemia using conventional (G-banding) and molecular (comparative genomic hybridisation (CGH) and fluorescence in situ hybridisation (FISH)) methods to determine whether an integrative screening approach increases abnormality detection rate.
  • Interphase FISH (i-FISH) was selectively carried out at disease diagnosis on patients with acute lymphoblastic leukaemia and acute myeloid leukaemia using conventional methods.
  • However, when both screening methods were integrated, the abnormality detection rate increased to 66.7%.
  • CONCLUSIONS: The advantages and disadvantages of using G-banding, CGH and i-FISH as either stand-alone or integrated screening methods for the detection and characterisation of genomic imbalances in acute leukaemia are clearly demonstrated.
  • Abnormality detection rate significantly increased when an integrated screening approach was employed which could potentially provide valuable information for risk stratification in patients with acute leukaemia.
  • [MeSH-major] Chromosome Aberrations. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Chromosome Banding / methods. DNA, Neoplasm / genetics. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence / methods. Interphase. Karyotyping. Male. Middle Aged. Nucleic Acid Hybridization / methods

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474541.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


39. Jabłoński M, Dudek D, Furgał M, Datka W, Zieba A: [Manfred Cierpka Questionnaire usefulness in the analysis of perception of familiar support in patients with acute leukaemia]. Psychiatr Pol; 2007 Nov-Dec;41(6):799-812
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Manfred Cierpka Questionnaire usefulness in the analysis of perception of familiar support in patients with acute leukaemia].
  • This study discusses the meaning of social support in somatic disorders, particularly acute leukaemia in the context of family functioning.
  • METHOD: The study included 36 subjects, 21 men and 15 women, with diagnosis of acute leukaemia.
  • The level of depression symptoms was Manfred Cierpka questionnaire usefulness in the analysis of perception of familiar support in patients with acute leukaemia by the set of questionnaires.
  • The level of disease symptoms was estabilished on the basis of several clinical variables and procedures, during a one year course of the disease.
  • The results of the family functioning questionnaire are related to the sustaining of depressive symptoms in the course of the disease.
  • [MeSH-major] Depression / diagnosis. Family Relations. Leukemia / psychology. Quality of Life / psychology. Social Support
  • [MeSH-minor] Acute Disease / psychology. Adult. Analysis of Variance. Anxiety / diagnosis. Female. Health Status. Humans. Male. Personality Assessment. Poland. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540423.001).
  • [ISSN] 0033-2674
  • [Journal-full-title] Psychiatria polska
  • [ISO-abbreviation] Psychiatr. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


40. Pawelec K, Trzcińska A, Siennicka J, Malinowska I, Litwińska B: [Epstein-Barr infections in children with acute leukaemia. Preliminary report]. Med Wieku Rozwoj; 2008 Jan-Mar;12(1):485-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr infections in children with acute leukaemia. Preliminary report].
  • THE AIM: of this study was to evaluate the effectiveness of laboratory methods used to detect EBV and to monitor EBV infections in children with acute leukaemia.
  • MATERIALS AND METHODS: we conducted the study on 30 children with acute leukaemia.
  • The control group were 11 subjects, without chronic or neoplastic disease, undergoing routine laboratory tests in the Virology Department.
  • Results of serological investigations indicated the type of EBV infection in our patients.
  • 3. In order to assess the effectiveness of serological and molecular methods in evaluation of EBV infection type in children with acute leukaemia, it is necessary to investigate a larger group of patients and taken at least three times.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663268.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


41. Beutel G, Meyer J, Ma L, Yin S, Eder M, von Neuhoff N, Wilkens L, Wei J, Hertenstein B, Heil G, Schlegelberger B, Ganser A, Li Z, Baum C: Expression of the p75 neurotrophin receptor in acute leukaemia. Br J Haematol; 2005 Oct;131(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the p75 neurotrophin receptor in acute leukaemia.
  • Recently, we observed a myeloid leukaemia in mice transplanted with dLNGFR-modified bone marrow cells.
  • Retroviral-mediated expression of dLNGFR was suspected to contribute to the murine leukaemia.
  • This led us to investigate the expression of p75NTR in human leukaemia.
  • Expression of p75NTR was observed in nine of 119 (8%) adult patients with acute leukaemia by flow cytometry analysis, particularly in acute lymphoblastic leukaemia (26%).
  • [MeSH-major] Leukemia / metabolism. Receptor, Nerve Growth Factor / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Child, Preschool. Cohort Studies. Female. Flow Cytometry. Gene Expression. Genes, abl. Humans. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173964.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, Nerve Growth Factor
  •  go-up   go-down


42. Gooneratne LV, Wijeratne MD, Gunasekara HD, Tudawe MN: Acute leukaemia of ambiguous lineage--a diagnostic dilemma. Ceylon Med J; 2009 Jun;54(2):51-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukaemia of ambiguous lineage--a diagnostic dilemma.
  • Acute leukaemia of ambiguous lineage (ALAL) is a rare form of leukaemia in which morphologic, cytochemical and immuno-phenotypic features of the proliferating blasts lack sufficient evidence to classify them as myeloid or lymphoid in origin or have characteristics of both myeloid and lymphoid cells.
  • We report a 22-year-old man presenting with clinical features of an acute lymphoblastic leukaemia but blasts in his blood and bone marrow with morphological features of myeloblasts.
  • We highlight the importance of correlating clinical features with cellular morphology when diagnosing acute leukaemias, especially when facilities for flowcytometry are not routinely available.
  • [MeSH-major] Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670549.001).
  • [ISSN] 0009-0875
  • [Journal-full-title] The Ceylon medical journal
  • [ISO-abbreviation] Ceylon Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sri Lanka
  •  go-up   go-down


43. Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F: Biphenotypic acute leukaemia: a case series. Br J Haematol; 2007 Jul;138(2):213-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphenotypic acute leukaemia: a case series.
  • Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia.
  • Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear.
  • No specific chromosomal abnormality was identified.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunophenotyping. Leukemia, Myeloid, Acute / drug therapy. Male. Methotrexate / therapeutic use. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593028.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; HCVAD protocol
  •  go-up   go-down


44. Furuya ME, González-Martínez F, Vargas MH, Miranda-Novales MG, Bernáldez-Ríos R, Zúñiga-Vázquez G: Guidelines for diagnosing and treating pulmonary infiltrates in children with acute leukaemia: impact of timely decisions. Acta Paediatr; 2008 Jul;97(7):928-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for diagnosing and treating pulmonary infiltrates in children with acute leukaemia: impact of timely decisions.
  • AIM: Children with leukaemia are at increased risk of pulmonary complications, often with unspecific clinical data, delayed diagnosis and a high mortality rate.
  • METHODS: Clinical charts of children with acute leukaemia and suspicion of pulmonary involvement were reviewed.
  • RESULTS: Children from group I (n=32) and group II (n=28) did not differ with respect to age (9.3+/-0.5 years old, mean+/-SEM), gender, type, risk and stage of leukaemia, anaemia and neutropenia.
  • Total length of hospital stay and hospitalization due to the pulmonary disease were shorter in group I than in group II (14.8+/-2.1 vs. 28.5+/-3.7 days, p=0.0016; and 10.8+/-1.0 vs. 18.4+/-1.8 days, p=0.0003, respectively).
  • CONCLUSIONS: Diagnostic-therapeutic guidelines that incorporate timely decisions constitute a useful algorithm to reduce the length of hospital stay and mortality in children with acute leukaemia and pulmonary infiltrates.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Lung Diseases / diagnosis. Lung Diseases / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430068.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


45. Goubin A, Auclerc MF, Auvrignon A, Patte C, Bergeron C, Hémon D, Clavel J: Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990-2000). Eur J Cancer; 2006 Mar;42(4):534-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990-2000).
  • This article describes the survival after childhood acute leukaemia (AL) and non-Hodgkin's lymphoma (NHL) of French population aged less than 15 years.
  • The French National Registry of Childhood Leukaemia and Lymphoma recorded 3995 cases of acute lymphoblastic leukaemia (ALL), 812 of acute myeloid leukaemia (AML) and 1137 of NHL over the period from 1990 to 2000.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412629.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


46. Zhang J, Mi YC, Wang Y, Lin D, Li W, Sun XM, Zhou K, Bian SG, Wang JX: [Study on the clinical characteristics of adult biphenotypic acute leukaemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jan;30(1):18-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the clinical characteristics of adult biphenotypic acute leukaemia].
  • OBJECTIVE: To analyze the clinical and biological characteristics and prognosis of adult biphenotypic acute leukaemia (BAL).
  • The chemotherapy regimens were accordingly for acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML) or for both ALL and AML.
  • (1) The incidence of BAL in acute leukaemias was 6.7%, with a male predominance and 52.3% of BAL patients had WBC > or = 30 x 10(9)/L and 16.9% WBC > or = 100 x 10(9)/L. (2) Percentages of coexpression of myeloid and B lymphoid antigens were 81.5%, of myeloid and T lymphoid antigens 10.8%, of myeloid, B- and T lymphoid antigens 4.6%, and of B and T lymphoid antigens 3.1%. (3) Normal and abnormal karyotypes accounted for 41.5% and 58.5%, respectively in 53 BAL patients with karyotype analysis.
  • (1) High white blood cell count and coexpression of myeloid/B lymphoid antigens are common in BAL. (2) Abnormal karyotypes and Ph (+) or bcr-abl( +) often happen. (3) The treatment outcome of BAL is poor.
  • [MeSH-major] Leukemia, Biphenotypic, Acute

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563029.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


47. Mallol-Mesnard N, Menegaux F, Auvrignon A, Auclerc MF, Bertrand Y, Nelken B, Robert A, Michel G, Margueritte G, Perel Y, Méchinaud F, Bordigoni P, Leverger G, Baruchel A, Hémon D, Clavel J: Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). Int J Epidemiol; 2007 Feb;36(1):110-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE).
  • BACKGROUND: In 2002, a poster alerted the French health authorities to the possibility that the risk of childhood leukaemia might be increased by hepatitis B vaccination.
  • Elucidating the role of vaccination in the aetiology of childhood acute leukaemia (AL) was therefore included in the objectives of an ongoing national study.
  • METHODS: The ESCALE study was a French national population-based case-control study conducted in France in 2003 and 2004 in order to investigate the role of infectious, environmental and genetic factors in four childhood neoplastic diseases (leukaemia, lymphoma, neuroblastoma and brain tumour).
  • RESULTS: No association between vaccination and the risk of childhood AL: acute lymphoblastic leukaemia or acute myeloblastic leukaemia was observed.
  • No relationship between the risk of leukaemia and the type of vaccine, number of doses of each vaccine, total number of injections, total number of vaccine doses or number of early vaccinations was evidenced.
  • CONCLUSION: The study did not show any evidence of a role of vaccination in the aetiology of childhood leukaemia.
  • [MeSH-major] Hepatitis B Vaccines / adverse effects. Leukemia / immunology
  • [MeSH-minor] Adolescent. Age Distribution. Case-Control Studies. Child. Child, Preschool. Drug Administration Schedule. Female. France / epidemiology. Humans. Infant. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / virology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Risk Assessment / methods. Sex Distribution. Vaccination / adverse effects

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2004 Apr;13(2):97-103 [15100575.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1100-9 [15951359.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):175-8 [10487630.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):590-4 [3463201.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Arch Pediatr. 2003 May;10(5):403-9 [12878332.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Bull World Health Organ. 1999;77(3):224-9 [10212512.001]
  • (PMID = 17227780.001).
  • [ISSN] 0300-5771
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Other-IDs] NLM/ HALMS168385; NLM/ PMC2292812
  •  go-up   go-down


48. Niedzielska E, Niedzielska M, Chybicka A: [Allelic variants of TPMT and the risk of leucopenia and neutropenia in patients treated for acute leukaemia]. Med Wieku Rozwoj; 2009 Jul-Sep;13(3):180-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allelic variants of TPMT and the risk of leucopenia and neutropenia in patients treated for acute leukaemia].
  • MATERIAL AND METHODS: The examined group consisted of 210 patients (121 boys, 89 girls) aged between 1 and 18 (median age 7 years, average age 8 years, SD+/-5.32) treated for leukaemia (acute lymphoblastic leukaemia ALL: n=167; acute myeloblastic leukaemia AML: n=43).
  • RESULTS: Analysis of changes in selected blood count parameters in the whole treatment period in the acute leukaemia group indicated that in the TPMT *2, *3A or *3C polymorphism carriers' group there is a statistically significant decrease in the white blood cell count (p=0.0025) and in the neutrophil count (p=0.019).
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Leukopenia / genetics. Methyltransferases / genetics. Neutropenia / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20081263.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  •  go-up   go-down


49. Santos FA, Pochapski MT, Pilatti GL, Kozlowski VA Jr, Goiris FA, Groppo FC: Severe necrotizing stomatitis and osteomyelitis after chemotherapy for acute leukaemia. Aust Dent J; 2009 Sep;54(3):262-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe necrotizing stomatitis and osteomyelitis after chemotherapy for acute leukaemia.
  • BACKGROUND: Leukaemia is a malignant neoplasm characterized by clonal proliferation of white blood cells within the bone marrow.
  • Despite an increase in the white blood cell count, the leukaemic leukocytes are non-functional.
  • METHODS: This case report describes severe maxillary and mandibular necrotizing stomatitis and osteomyelitis in a young female patient after chemotherapy for acute leukaemia.
  • The patient received a daily preventive protocol consisting of oral hygiene care, including twice daily brushing, and mouthrinses with a solution of chlorhexidine.
  • Thirty-two months after presentation of the initial symptoms, the patient died due to complications related to leukaemia recurrence (haemorrhage, sepsis and respiratory distress syndrome).
  • CONCLUSIONS: Dental monitoring during cancer treatment is imperative in order to emphasize the importance of dental plaque control and the maintenance of a healthy periodontal condition throughout medical treatment.
  • [MeSH-major] Alveolar Bone Loss / complications. Drug-Related Side Effects and Adverse Reactions. Leukemia, Myeloid, Acute / drug therapy. Osteomyelitis / complications. Stomatitis / complications

  • Genetic Alliance. consumer health - Osteomyelitis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19709116.001).
  • [ISSN] 1834-7819
  • [Journal-full-title] Australian dental journal
  • [ISO-abbreviation] Aust Dent J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Immunosuppressive Agents; BBX060AN9V / Hydrogen Peroxide; MOR84MUD8E / chlorhexidine gluconate; R4KO0DY52L / Chlorhexidine
  •  go-up   go-down


50. Faure C, Mollié A, Bellec S, Guyot-Goubin A, Clavel J, Hémon D: Geographical variations in the incidence of childhood acute leukaemia in France over the period 1990-2004. Eur J Cancer Prev; 2009 Aug;18(4):267-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographical variations in the incidence of childhood acute leukaemia in France over the period 1990-2004.
  • Spatial variations in childhood acute leukaemia (AL) incidence rates were investigated by département, in mainland France, over the period 1990-2004.
  • French National Registry of Childhood Haematological Malignancies data and population counts by type of leukaemia (AL, acute lymphoblastic leukaemia, acute myeloblastic leukaemia), time period (1990-2004, 1990-1994, 1995-1999 and 2000-2004), sex, and age group (0-14, 0-4, 5-9 and 10-14 years of age) were considered.
  • The overall homogeneity of the relative risks of leukaemia was tested, as well as comparison to 1 of each relative risk by the exact Poisson test.
  • The associated maps were slightly heterogeneous; the smoothed SIRs of overall acute lymphoblastic leukaemia of the south-west départements were slightly higher than those of the north-east.
  • The results, however, did not remain stable when investigated by leukaemia type, time period, sex or age group.
  • [MeSH-major] Demography. Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444126.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


51. Shaw BE, Russell NH: Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant; 2008 Mar;41(5):495-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.
  • The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952130.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  • [Number-of-references] 91
  •  go-up   go-down


52. Wyndham M: Acute leukaemia in childhood. Community Pract; 2007 Jul;80(7):19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukaemia in childhood.
  • [MeSH-major] Leukemia, Myeloid, Acute. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702481.001).
  • [ISSN] 1462-2815
  • [Journal-full-title] Community practitioner : the journal of the Community Practitioners' & Health Visitors' Association
  • [ISO-abbreviation] Community Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


53. Nihtinen A, Anttila VJ, Elonen E, Juvonen E, Volin L, Ruutu T: Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia. Eur J Haematol; 2008 May;80(5):391-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia.
  • OBJECTIVES: The efficacy of fluconazole prophylaxis to prevent invasive candida infections in patients with acute leukaemia receiving chemotherapy is not clear.
  • Fluconazole prophylaxis might increase the number of bacteraemias and cause outbreaks of non-albicans yeast infections.
  • METHODS: All 1089 adult acute leukaemia patients treated with chemotherapy in 1978-2004 at Helsinki University Central Hospital were included.
  • The incidence of non-albicans infections did not increase in the fluconazole prophylaxis group.
  • A larger proportion of patients developed bacteraemias in the prophylaxis group (65%) compared to the non-prophylaxis group (52%) (P < 0.001).
  • Invasive candida infections were more common in patients with acute lymphoblastic leukaemia than those with acute myeloid leukaemia, 10.5% vs. 5.9% (P = 0.008).
  • CONCLUSIONS: Fluconazole prophylaxis was effective in preventing invasive candida infections in patients with acute leukaemia without increasing non-albicans infections.
  • [MeSH-major] Bacteremia / prevention & control. Candidiasis / drug therapy. Candidiasis / prevention & control. Fluconazole / pharmacology. Leukemia

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18221387.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 8VZV102JFY / Fluconazole
  •  go-up   go-down


54. Møller T, Nielsen OJ, Welinder P, Dünweber A, Hjerming M, Moser C, Kjeldsen L: Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. Eur J Haematol; 2010 Apr;84(4):316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia.
  • Traditionally, patients with acute leukaemia are admitted to hospital during chemotherapy-induced pancytopenia, although a few recent reports have reported the feasibility and safety of outpatient treatment.
  • We have developed an outpatient treatment programme for patients with acute leukaemia incorporating comprehensive patient education for self-care management at home during pancytopenia and involvement of patients in care of their tunnelled central venous catheter (CVC).
  • Herein, we report the results of outpatient treatment of 60 patients with acute leukaemia (54 with acute myeloid leukaemia) followed prospectively in the period from March 2004 to 2007.
  • The majority of the patients were able to take care of their CVC including change in dressing and heparin flushing.
  • We conclude that outpatient treatment of patients with acute leukaemia is feasible and safe.
  • [MeSH-major] Ambulatory Care / methods. Anti-Infective Agents / administration & dosage. Leukemia / drug therapy. Neutropenia / drug therapy. Pancytopenia / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002732.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  •  go-up   go-down


55. Mucha M, Pawelec K, Matysiak M: [The course of epstein-barr virus and cytomegalovirus infection in children with acute leukaemia during chemotherapy]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1062-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The course of epstein-barr virus and cytomegalovirus infection in children with acute leukaemia during chemotherapy].
  • AIM: To assess the course of EBV and CMV infection among children with acute leukaemia during chemotherapy with the aim to establish an efficient monitoring strategy.
  • MATERIAL AND METHODS: We have analyzed 28 children with acute leukaemia (age: 4 months-16 years) treated in the Department of Paediatric Haematology and Oncology, Medical University of Warsaw between 2004 and 2007 according to accepted chemotherapy protocols.
  • CONCLUSIONS: In children with leukaemia during chemotherapy primary and reactivation EBV infection occurred more often than CMV infection.
  • [MeSH-major] Cytomegalovirus Infections / epidemiology. Epstein-Barr Virus Infections / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Comorbidity. Disease Progression. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531827.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


56. Marks DI, Khattry N, Cummins M, Goulden N, Green A, Harvey J, Hunt LP, Keen L, Robinson SP, Steward CG, Cornish JM: Haploidentical stem cell transplantation for children with acute leukaemia. Br J Haematol; 2006 Jul;134(2):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploidentical stem cell transplantation for children with acute leukaemia.
  • Some children with relapsed or high-risk acute leukaemia have an improved outcome if they have an allogeneic stem cell transplant, preferably from a sibling or well-matched unrelated donor.
  • However, some children do not have these options or there is an urgent need to proceed to transplant because of disease status.
  • We have investigated the role of haploidentical family members as donors in 34 patients with acute leukaemia (median age 11 years, range 1-16 years).
  • Patients were conditioned with cyclophosphamide and total body irradiation (14.4 Gy in eight fractions) and received T-cell depleted peripheral blood stem cell grafts with a median CD34 cell dose of 13.8 x 10(6)/kg (range 4.2-35.1) and 0.7 x 10(4) CD3-positive cells/kg.
  • Eight patients have survived disease-free with a median follow up of 62 months.
  • Haploidentical stem cell transplantation can produce medium term disease-free survival in a proportion of children with high-risk or relapsed acute leukaemia.
  • None of the nine patients with acute myeloid leukaemia not in remission have survived.
  • [MeSH-major] Leukemia / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adolescent. Cause of Death. Child. Child, Preschool. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Haplotypes. Histocompatibility Testing / methods. Humans. Infant. Leukapheresis. Lymphocyte Count. Male. Opportunistic Infections / etiology. Recurrence. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome


57. Pogorzala M, Styczynski J, Kurylak A, Debski R, Wojtkiewicz M, Wysocki M: Health-related quality of life among paediatric survivors of primary brain tumours and acute leukaemia. Qual Life Res; 2010 Mar;19(2):191-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life among paediatric survivors of primary brain tumours and acute leukaemia.
  • PURPOSE: Comparative assessment of the HRQL of paediatric survivors of brain tumours (BT) and of acute leukaemia against a population of their healthy peers.
  • METHODS: The study consisted of patients who had completed treatment for BT (n=36) or acute leukaemia (n=35) and were aged between 8 and 19.
  • The influence of selected factors (sex, age, time from the end of treatment and type of treatment) on the HRQL result was analysed.
  • RESULTS: In all the aspects analysed (total, physical, psychosocial, emotional, social and school functioning), the HRQL of BT and leukaemia survivors was significantly lower in comparison to their healthy peers.
  • The HRQL of patients after BT treatment was also significantly lower than that of the survivors of leukaemia.
  • [MeSH-major] Central Nervous System Neoplasms / psychology. Leukemia, Myeloid, Acute / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Quality of Life / psychology. Sickness Impact Profile. Survivors / psychology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Springer Science+Business Media B.V. 2010
  • (PMID = 20077142.001).
  • [ISSN] 1573-2649
  • [Journal-full-title] Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
  • [ISO-abbreviation] Qual Life Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Elter T, Stipanov M, Heuser E, von Bergwelt-Baildon M, Bloch W, Hallek M, Baumann F: Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma? Int J Hematol; 2009 Sep;90(2):199-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma?
  • Patients undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma not only suffer from the direct side effects of chemotherapy such as infections due to long-lasting immuno-suppression and aplasia, but also from marked fatigue and the inability to do normal physical activity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Exercise Therapy. Leukemia / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Anemia / etiology. Anemia / physiopathology. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Feasibility Studies. Female. Humans. Male. Middle Aged. Physical Fitness. Pilot Projects. Quality of Life. Randomized Controlled Trials as Topic. Sports. Thrombocytopenia / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19629631.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Ohyashiki JH, Hisatomi H, Nagao K, Honda S, Takaku T, Zhang Y, Sashida G, Ohyashiki K: Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells. Br J Cancer; 2005 May 23;92(10):1942-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells.
  • Functionally active telomerase is affected at various steps including transcriptional and post-transcriptional levels of major telomerase components (hTR and human telomerase reverse transcriptase (hTERT)).
  • Fresh leukaemia cells obtained from 38 consecutive patients were used in this study.
  • An understanding of the complexities of telomerase gene regulation in biologically heterogeneous leukaemia cells may offer new therapeutic approaches to the treatment of acute leukaemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / enzymology. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Telomerase / analysis. Telomerase / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Dec 2;402(6761):551-5 [10591218.001]
  • [Cites] Neoplasia. 2000 Sep-Oct;2(5):426-32 [11191109.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):593-8 [11179492.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):644-9 [11267974.001]
  • [Cites] Nature. 2001 Sep 27;413(6854):432-5 [11574891.001]
  • [Cites] Nucleic Acids Res. 2001 Dec 1;29(23):4818-25 [11726691.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):680-7 [11850796.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):688-97 [11850797.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2168-70 [12090986.001]
  • [Cites] J Pathol. 2002 Sep;198(1):37-46 [12210061.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):257-65 [12398889.001]
  • [Cites] Lancet. 2003 Jun 7;361(9373):1993-4 [12801777.001]
  • [Cites] Blood. 2003 Aug 1;102(3):916-8 [12676774.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):193-7 [12869302.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6849-56 [12972604.001]
  • [Cites] Curr Med Res Opin. 2003;19(6):470-2 [14594517.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):127-31 [14654914.001]
  • [Cites] Nucleic Acids Res. 2004;32(1):371-9 [14729921.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1236-41 [7544491.001]
  • [Cites] Science. 1997 Aug 15;277(5328):955-9 [9252327.001]
  • [Cites] Cell. 1997 Aug 22;90(4):785-95 [9288757.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2011-9 [9328464.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6394-401 [9343401.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):498-502 [9398860.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4168-72 [9751630.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):619-25 [9815729.001]
  • [Cites] Gene. 1999 May 17;232(1):97-106 [10333526.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3936-42 [15319288.001]
  • (PMID = 15827550.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2361762
  •  go-up   go-down


60. Ellis R, Boggild M: Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler; 2009 Apr;15(4):505-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
  • BACKGROUND: Therapy-related acute leukaemia (TRAL) is a concern for neurologists and patients when considering treatment with Mitoxantrone for multiple sclerosis (MS).
  • RESULTS: Case-series including 5472 patients were identified; mean dose of Mitoxantrone was 74.2 mg/m(2) (range:12-120 mg/m(2)).
  • Acute Myelocytic Leukaemia and Acute Promyelocytic Leukaemia represented 46.4% each of the leukaemia subtypes.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / epidemiology. Mitoxantrone / adverse effects. Multiple Sclerosis / drug therapy. Multiple Sclerosis / epidemiology
  • [MeSH-minor] Acute Disease. Adult. Databases, Factual. Female. Humans. Leukemia, Promyelocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / epidemiology. Male. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251838.001).
  • [ISSN] 1352-4585
  • [Journal-full-title] Multiple sclerosis (Houndmills, Basingstoke, England)
  • [ISO-abbreviation] Mult. Scler.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


61. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM: The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol; 2006 Feb;132(4):398-409
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of gemtuzumab ozogamicin in acute leukaemia therapy.
  • Gemtuzumab ozogamicin (GO) is an immunoconjugate that binds to CD33 on the surface of acute myeloid leukaemia (AML) blasts and, after internalisation, releases a cytotoxic drug, calicheamicin.
  • GO therapy at 9 mg/m(2) is complicated with hepatic veno-occlusive disease in 5-10% of patients, particularly prior to or following stem cell transplantation.
  • GO is probably most active in acute promyelocytic leukaemia (APL).
  • Case reports suggest that GO also has activity in CD33-positive acute lymphoblastic leukaemia.
  • [MeSH-major] Aminoglycosides / administration & dosage. Aminoglycosides / therapeutic use. Antibiotics, Antineoplastic / administration & dosage. Antibodies, Monoclonal / therapeutic use. Immunotoxins / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Antibodies, Monoclonal, Humanized. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance. Enediynes. Humans. Protein Binding. Randomized Controlled Trials as Topic. Recurrence. Sialic Acid Binding Ig-like Lectin 3

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412015.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Enediynes; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab; 108212-75-5 / calicheamicin gamma(1)I
  • [Number-of-references] 82
  •  go-up   go-down


62. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJ, Cloos J, Joenje H, Reinhardt D, Ossenkoppele GJ, Zwaan CM, Waisfisz Q: Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol; 2008;30(4):299-306
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia.
  • Fanconi anaemia (FA) patients have an inherited defect in this pathway and are strongly predisposed to the development of acute myeloid leukaemia (AML).
  • However, only a single leukaemic case with methylation of one of the FA-BRCA genes has been described to date, i.e. methylation of FANCF in cell line CHRF-288.
  • We investigated the presence of aberrant methylation in 11 FA-BRCA genes in sporadic cases of leukaemia.
  • METHODS: We analyzed promoter methylation in 143 AML bone marrow samples and 97 acute lymphoblastic leukaemia (ALL) samples using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA).
  • CONCLUSION: Hypermethylation of promoter regions from FA-BRCA genes does occur in sporadic leukaemia, albeit infrequently.
  • This instability may have contributed to the occurrence of the leukaemia.
  • [MeSH-major] Bone Marrow Cells / enzymology. DNA Methylation. Fanconi Anemia Complementation Group C Protein / genetics. Fanconi Anemia Complementation Group L Protein / genetics. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Child. Child, Preschool. Cross-Linking Reagents / therapeutic use. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. Fanconi Anemia Complementation Group Proteins / genetics. Humans. Mitomycin / therapeutic use. Tumor Stem Cell Assay

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607065.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / FANCC protein, human; 0 / Fanconi Anemia Complementation Group C Protein; 0 / Fanconi Anemia Complementation Group Proteins; 50SG953SK6 / Mitomycin; EC 2.1.1.- / DNA Modification Methylases; EC 6.3.2.19 / FANCL protein, human; EC 6.3.2.19 / Fanconi Anemia Complementation Group L Protein
  • [Other-IDs] NLM/ PMC4618910
  •  go-up   go-down


63. Ak Y, Demirel G, Gülbas Z: MDR1, MRP1 and LRP expression in patients with untreated acute leukaemia: correlation with 99mTc-MIBI bone marrow scintigraphy. Nucl Med Commun; 2007 Jul;28(7):541-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDR1, MRP1 and LRP expression in patients with untreated acute leukaemia: correlation with 99mTc-MIBI bone marrow scintigraphy.
  • BACKGROUND: Chemotherapy failure linked to multidrug-resistance (MDR) plays an important role in many cancer types, including leukaemia.
  • We assessed the bone marrow uptake of (99m)Tc-MIBI and its correlation with messenger RNA (mRNA) levels of MDR1, multidrug-resistance associated protein-1 (MRP1) and lung resistance protein (LRP) in acute leukaemia.
  • METHODS: A total of 26 patients (age range 17-72 years; mean age 51.88+/-2.52 years) with newly diagnosed acute leukaemia were included in the study.
  • The expression of MDR1, MRP1 and LRP on mRNA levels were assessed by quantitative RT-PCR in the blast cells.
  • CONCLUSION: Increased expression of MDR1 and MRP1 correlates with a low accumulation of (99m)Tc-MIBI in bone marrow areas in patients with acute leukaemia. (99m)Tc-MIBI bone marrow scintigraphy can identify the MDR1 and MRP1 phenotype, but not LRP, in patients with acute leukaemia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia / metabolism. Leukemia / radionuclide imaging. Multidrug Resistance-Associated Proteins / metabolism. Organotechnetium Compounds. P-Glycoprotein / metabolism. Somatostatin / analogs & derivatives. Vault Ribonucleoprotein Particles / metabolism

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538395.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Organotechnetium Compounds; 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1; 51110-01-1 / Somatostatin; 9M48M2SF02 / technetium Tc 99m depreotide
  •  go-up   go-down


64. Potenza L, Riva G, Luppi M, Torelli G: Pneumonia in acute leukaemia: blossoming culprits. Br J Haematol; 2005 Feb;128(4):411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumonia in acute leukaemia: blossoming culprits.
  • [MeSH-major] Opportunistic Infections / complications. Pneumonia, Bacterial / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Pseudomonas Infections / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686449.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Lazarevic V, Paltiel O, Georgievski B: Trends in acute leukaemia incidence in adults in the Republic of Macedonia (1993-2003)--a descriptive epidemiological study. Prilozi; 2008 Jul;29(1):45-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in acute leukaemia incidence in adults in the Republic of Macedonia (1993-2003)--a descriptive epidemiological study.
  • OBJECTIVE: To analyse trends in incidence rates of acute leukaemia in patients aged 15 and over admitted to hospital.
  • RESULTS: The crude incidence rates of acute leukaemia in adults during this period increased substantially (p for overall trend < 0.001).
  • CONCLUSIONS: During a short period of time (11 years) we have noted an increase in the incidence rates of acute leukaemia in our population aged 15 years and above.
  • In addition, according to the census results in 1994 and 2002 the proportion of people aged 65 and above increased by 30.5% implying that this demographic change could account for part of the relative increase in the incidence rates of acute leukaemia.
  • What is already known on this topic: The risk of acute leukaemia increases by age and it is higher in males than in females.
  • WHAT THIS STUDY ADDS: The incidence rates are equal between the sexes; the increase in risk of acute leukemia in females could be due to environmental risk factor.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708999.001).
  • [ISSN] 0351-3254
  • [Journal-full-title] Prilozi
  • [ISO-abbreviation] Prilozi
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Dekio I, Anzai H, Ohyama M, Tanikawa A, Amagai M, Yokoyama K, Okamoto S, Tanaka M: Aleukaemic leukaemia cutis as an initial manifestation of myeloid/NK cell precursor acute leukaemia. J Eur Acad Dermatol Venereol; 2006 Apr;20(4):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aleukaemic leukaemia cutis as an initial manifestation of myeloid/NK cell precursor acute leukaemia.
  • Aleukaemic leukaemia cutis is a rare condition characterized by infiltration of leukaemic cells into the skin before they appear in the peripheral blood.
  • We report a case of an aleukaemic leukaemia cutis, which had a history of exposure to atomic bomb radiation.
  • The results of immunohistochemistry of the skin biopsy specimen and flow cytometry of the peripheral blood indicated the rare phenotype of myeloid/NK cell precursor acute leukaemia.
  • This is the first case report of myeloid/NK cell precursor acute leukaemia presenting as aleukaemic leukaemia cutis in the English literature, and awareness of this clinical presentation may be important to reach the correct diagnosis.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia / diagnosis. Leukemia, Myeloid / diagnosis. Leukemia, Radiation-Induced / diagnosis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643148.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


67. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, Hovi L, Jonmundsson G, Lie SO, Glomstein A, Hasle H, Nordic Society of Paediatric Haematology and Oncology (NOPHO): Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol; 2005 Mar;128(6):797-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukaemia in children with Down syndrome: a population-based Nordic study.
  • To determine the epidemiology and outcome of children with Down syndrome (DS) diagnosed with acute leukaemia in the Nordic countries, data registered in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) population-based leukaemia registry were analysed.
  • Of 3494 children with acute leukaemia diagnosed between July 1984 and December 2001, 136 patients (3.9%) with DS were identified.
  • 2.1% of the children with acute lymphoid leukaemia (ALL) and 14.0% of the children with acute myeloid leukaemia (AML) had DS.
  • In ALL, DS patients had similar age and sex distribution and no major differences in blood counts compared with non-DS children.
  • None of the DS patients had T cell leukaemia.
  • Outcome was inferior to that of non-DS children and treatment results did not improve over time.
  • DS patients with AML had significantly lower platelet and white blood cell counts and two-thirds were type M7 as according to the French-American-British classification.
  • [MeSH-major] Down Syndrome / complications. Leukemia, Myeloid / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Disease. Age Distribution. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Norway / epidemiology

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755283.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Caporaso P, Turriziani M, Venditti A, Marchesi F, Buccisano F, Tirindelli MC, Alvino E, Garbin A, Tortorelli G, Toppo L, Bonmassar E, D'Atri S, Amadori S: Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. DNA Repair (Amst); 2007 Aug 1;6(8):1179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
  • Previous studies indicated that dacarbazine and Temozolomide could be highly effective against refractory acute leukaemia.
  • High levels of O(6)-methylguanine-DNA methyltransferase (MGMT) or a defective mismatch repair (MMR) system, are associated with cellular resistance to triazenes.
  • In the early 1970s we discovered that, in vivo, triazene compounds induce the appearance of novel transplantation antigens in murine leukaemia ("Chemical Xenogenization", CX).
  • Non-self peptides presented by class I MHC molecules are generated by triazene-induced somatic mutations, affecting retroviral sequences that are detectable in the mouse genome.
  • Here we present the results of pilot study which is in progress in patients with refractory/relapsed acute leukaemia.
  • Six out of eight patients showed partial or complete disappearance of blast cells in peripheral blood or in bone marrow.
  • We observed severe and long-lasting myelosuppression, accompanied by limited non-haematological toxicity.
  • Up to now, two patients are alive (after 9 and 10 months, respectively), four died of opportunistic infections and two of progressive disease.
  • This investigation confirms the potential role of triazenes in leukaemia and highlights the contribution of Lomeguatrib in overcoming drug resistance.
  • Further studies are required to establish whether Temozolomide can induce CX in human leukaemia, and thus offer a new approach to control minimal residual disease.
  • [MeSH-major] Dacarbazine / analogs & derivatives. Interleukin-2 / therapeutic use. Leukemia / drug therapy. Leukemia / therapy. Purines / therapeutic use

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17500047.001).
  • [ISSN] 1568-7864
  • [Journal-full-title] DNA repair
  • [ISO-abbreviation] DNA Repair (Amst.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Enzyme Inhibitors; 0 / Interleukin-2; 0 / Purines; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 6.5.1.- / DNA Repair Enzymes; S79265T71M / lomeguatrib
  •  go-up   go-down


69. Bellec S, Hémon D, Rudant J, Goubin A, Clavel J: Spatial and space-time clustering of childhood acute leukaemia in France from 1990 to 2000: a nationwide study. Br J Cancer; 2006 Mar 13;94(5):763-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial and space-time clustering of childhood acute leukaemia in France from 1990 to 2000: a nationwide study.
  • This study aimed to investigate the spatial and space-time distributions of cases of childhood acute leukaemia (CL) during 1990-2000 over the whole French territory.
  • The presence of space-time interaction between the places of residence and the dates of diagnosis was investigated with the Knox's test.
  • Overall, a statistically significant spatial heterogeneity of a very small magnitude was observed in the incidence of CL over 1990-1994, but neither over 1995-2000 nor over the whole time period.
  • Cases older than 10 years living in the same area at diagnosis also tended to cluster within 6 months.
  • [MeSH-major] Leukemia / epidemiology
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Female. France / epidemiology. Geography. Humans. Incidence. Infant. Infant, Newborn. Male. Time Factors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Epidemiol Community Health. 1999 Mar;53(3):154-8 [10396492.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):91-6 [10211094.001]
  • [Cites] Biometrika. 1950 Jun;37(1-2):17-23 [15420245.001]
  • [Cites] J Epidemiol Community Health. 2005 Mar;59(3):221-2 [15709082.001]
  • [Cites] Eur J Cancer Prev. 2005 Apr;14(2):147-57 [15785319.001]
  • [Cites] Eur J Epidemiol. 2005;20(8):663-71 [16151879.001]
  • [Cites] Eur J Cancer. 2006 May;42(7):927-33 [16530405.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1571-6 [10789727.001]
  • [Cites] Biometrics. 1999 Jun;55(2):544-52 [11318212.001]
  • [Cites] Eur J Epidemiol. 2000;16(12):1111-6 [11484799.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):513-5 [12189547.001]
  • [Cites] Eur J Cancer Prev. 2004 Apr;13(2):97-103 [15100575.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):916-22 [15280917.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Biometrika. 1966 Jun;53(1):183-90 [5964055.001]
  • [Cites] J Natl Cancer Inst. 1971 Aug;47(2):329-36 [5559240.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Stat Med. 1995 Jan 15;14(1):17-26 [7701154.001]
  • [Cites] Stat Med. 1995 Apr 30;14(8):799-810 [7644860.001]
  • [Cites] Cancer Causes Control. 1995 Sep;6(5):383-8 [8547535.001]
  • [Cites] Stat Med. 1996 Apr 15-May 15;15(7-9):707-15 [9132898.001]
  • [Cites] Br J Cancer. 1997;75(3):457-63 [9020498.001]
  • [Cites] IARC Sci Publ. 1996;(135):21-7 [9103930.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):239-45 [9134248.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):818-24 [9514064.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):655-7 [10027345.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):439-44 [10448296.001]
  • (PMID = 16479258.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2374236
  •  go-up   go-down


70. Bacher U, Kohlmann A, Haferlach T: Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Br J Haematol; 2009 Jun;145(5):555-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
  • Gene expression profiling (GEP) enables the simultaneous investigation of the expression of tens of thousands of genes and was successfully introduced in leukaemia research a decade ago.
  • Aiming to better understand the diversity of genetic aberrations in acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), pioneer studies investigated and confirmed the predictability of many cytogenetic and molecular subclasses in AML and ALL.
  • In addition, GEP can define new prognostic subclasses within distinct leukaemia subgroups, as illustrated in AML with normal karyotype.
  • Finally, GEP might enable the detection of new molecular targets for therapy in patients with acute leukaemia.
  • Meanwhile, large multicentre studies, e.g. the Microarray Innovations in LEukaemia (MILE) study, prepare for a standardised introduction of GEP in leukaemia diagnostic algorithms, aiming to translate this novel methodology into clinical routine for the benefit of patients with the complex disorders of AML and ALL.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia / diagnosis. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Gene Expression. Gene Rearrangement. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344393.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 118
  •  go-up   go-down


71. Wang W, Wang XQ, Xu XP, Lin GW: Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group. J Int Med Res; 2010 Mar-Apr;38(2):432-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.
  • This study was designed to evaluate the prevalence of fms-like tyrosine kinase-3 (FLT3) gene mutations in the World Health Organization classified subtypes of acute leukaemia (AL), and their prognostic significance in terms of complete remission (CR), leukaemia-free survival (LFS) and overall survival (OS).
  • Of 468 patients, 374 (79.9%) had acute myeloid leukaemia (AML) and 83 (17.7%) had acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Biomarkers, Tumor / genetics. Leukemia, Myeloid, Acute / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515557.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


72. Borlenghi E, Cattaneo C, Capucci MA, Pan A, Quaresmini G, Franco F, Grazioli L, Carosi GP, Rossi G: Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol; 2007 Mar;86(3):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates.
  • Invasive pulmonary aspergillosis (IPA) is a frequently fatal complication in patients with acute leukaemia.
  • Because diagnosis is still difficult, non-invasive diagnostic criteria were recently proposed by MSG/IFICG/EORTC for study purposes.
  • We have analysed their usefulness in the clinical management of acute leukaemic patients with pulmonary infiltrates.
  • AML diagnosis and the first induction cycle were significant risk factors.
  • The diagnosis of "probable" IPA was made in seven patients (14%) and was strongly supported by the significant association of characteristic radiological lesions ("major" clinical criterion) with the positivity of one microbiological criterion (P = 0.026).
  • However, in 84.6% of cases, the diagnosis of "possible IPA" aspecifically derived from the association of two conditions, a new pulmonary infiltrate with symptoms of lower respiratory tract infection ("minor clinical criterion"), together with the definition of "susceptible" host, which applied to 100% of our leukaemic patients.
  • We conclude that, according to MSG/IFICG/EORTC criteria, a high number of pulmonary infiltrates would be diagnosed as IPA, but only a diagnosis of "proven/probable" IPA should be considered reliable in the clinical management of suspected IPA.
  • [MeSH-major] Aspergillosis, Allergic Bronchopulmonary / diagnosis. Aspergillosis, Allergic Bronchopulmonary / drug therapy. Leukemia / complications. Practice Guidelines as Topic
  • [MeSH-minor] Acute Disease. Adult. Aged. Antifungal Agents / therapeutic use. Ciprofloxacin / therapeutic use. Female. Humans. Itraconazole / therapeutic use. Male. Middle Aged. Models, Theoretical. Ofloxacin / therapeutic use. Reproducibility of Results. Treatment Outcome

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. Ofloxacin .
  • Hazardous Substances Data Bank. Itraconazole .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119965.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 304NUG5GF4 / Itraconazole; 5E8K9I0O4U / Ciprofloxacin; A4P49JAZ9H / Ofloxacin
  •  go-up   go-down


73. Al-Tonbary Y, Mansour AK, Ghazy H, Elghannam DM, Abd-Elghaffar HA: Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia. Int J Lab Hematol; 2009 Jun;31(3):320-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
  • In children with acute myelogenous leukaemia (AML), internal tandem duplication of the Flt3 gene (Flt3/ITD) was previously reported and correlated to poor prognosis.
  • Limited data are available about childhood acute lymphoblastic leukaemia (ALL).
  • We analysed bone marrow specimens from 55 newly diagnosed acute leukaemia cases including 30 AML and 25 ALL by genomic PCR for the presence of Flt3/ITD and correlated its presence with clinical outcome.
  • Lineage restriction analysis revealed that Flt3/ITD was not present in lymphocytes, suggesting a lack of stem cell involvement for this mutation.
  • Patients with Flt3/ITD appear to be refractory to primary induction therapy, and for those who achieve remission, there is a high rate of relapse and death so there may be an association between this type of mutation and patient outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336585.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


74. Vranova V, Mentzlova D, Oltova A, Linkova V, Zezulkova D, Filkova H, Mendelova D, Sterba J, Kuglik P: Efficacy of high-resolution comparative genomic hybridization (HR-CGH) in detection of chromosomal abnormalities in children with acute leukaemia. Neoplasma; 2008;55(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of high-resolution comparative genomic hybridization (HR-CGH) in detection of chromosomal abnormalities in children with acute leukaemia.
  • The efficient detection of chromosomal aberrations in childhood acute leukaemias presents a significant component in the diagnostics of this frequent malignant disease.
  • We used comparative genomic hybridization (CGH) and high-resolution comparative genomic hybridization (HR-CGH) to determine the frequency of chromosomal changes in 33 children with acute leukaemia (AL).
  • Cytogenetic and molecular cytogenetic analyses of 33 childhood acute leukaemias revealed chromosomal changes in total 31 (94 %) patients.
  • The evaluation of HR-CGH sensitivity proved that the minimal cell population of malignant cells in which a certain chromosomal change could be found was close to the 20 - 30 % level.
  • Supplementing G-banding and FISH with the HR-CGH diagnostic method increases the detection of unbalanced structural chromosomal rearrangements and can reveal small cell clones with gains and losses of whole chromosomes in hyperdiploid AL.
  • [MeSH-major] Chromosome Aberrations. Leukemia / genetics. Nucleic Acid Hybridization / methods
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Chromosome Banding. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Male

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190236.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


75. Haferlach T, Kohlmann A, Bacher U, Schnittger S, Haferlach C, Kern W: Gene expression profiling for the diagnosis of acute leukaemia. Br J Cancer; 2007 Feb 26;96(4):535-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling for the diagnosis of acute leukaemia.
  • An optimised diagnostic setting in acute leukaemias combines cytomorphology and cytochemistry, multiparameter immunophenotyping, cytogenetics, fluorescence in situ hybridisation, and polymerase chain reaction (PCR)-based assays.
  • This novel approach will hopefully become an essential tool for the molecular classification of acute leukaemias in the near future.
  • It can be anticipated that new biologically defined and clinically relevant subtypes of leukaemia will be identified based on their unique gene expression profiles.
  • [MeSH-major] Gene Expression Profiling. Leukemia / diagnosis. Leukemia / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Acute Disease. Humans. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Prognosis. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1124-9 [11158605.001]
  • [Cites] Blood. 2006 Jul 15;108(2):685-96 [16597596.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10008-13 [12105272.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3118-30 [12374679.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):149-58 [12696063.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1777-85 [12724484.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):396-405 [12800151.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Sep;55(1):29-36 [12949957.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Dec;16(4):645-52 [14592648.001]
  • [Cites] Leukemia. 2004 Jan;18(1):63-71 [14603332.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2646-54 [15251987.001]
  • [Cites] Nat Biotechnol. 1996 Dec;14(13):1675-80 [9634850.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):5-9 [9915493.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):299-307 [15609343.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1580-8 [15674343.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):113-27 [15751046.001]
  • [Cites] Blood. 2005 Aug 1;106(3):899-902 [15831697.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1189-98 [15878973.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6296-305 [16155012.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7209-19 [16243790.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):223-34 [16213152.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3747-54 [16109776.001]
  • [Cites] Haematologica. 2006 Jun;91(6):821-4 [16769585.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1385-92 [16761018.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • (PMID = 17146476.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2360048
  •  go-up   go-down


76. Zainal Muttakin AR, Tan AM: Mycobacterium fortuitum catheter-related sepsis in acute leukaemia. Singapore Med J; 2006 Jun;47(6):543-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycobacterium fortuitum catheter-related sepsis in acute leukaemia.
  • We report Mycobacterium fortuitum (M. fortuitum) catheter-related sepsis in a five-year-old boy with acute lymphoblastic leukaemia (ALL).
  • This is the first reported case of M. fortuitum infection seen in our paediatric oncology patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Catheters, Indwelling / microbiology. Mycobacterium Infections, Nontuberculous / complications. Mycobacterium fortuitum / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sepsis / etiology
  • [MeSH-minor] Acute Disease. Child, Preschool. Humans. Immunocompromised Host. Male

  • Genetic Alliance. consumer health - Mycobacterium fortuitum.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752025.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


77. Braham-Jmili N, Sendi-Senana H, Labiadh S, Ben Abdelali R, Ben Abdelaziz A, Khelif A, Saad A, Kortas M: [Haematological characteristics, FAB and WHO classification of 153 cases of myeloid acute leukaemia in Tunisia]. Ann Biol Clin (Paris); 2006 Sep-Oct;64(5):457-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Haematological characteristics, FAB and WHO classification of 153 cases of myeloid acute leukaemia in Tunisia].
  • [Transliterated title] Caractéristiques hématologiques et classification FAB et OMS de 153 cas de leucémies aiguës myéloïdes en Tunisie.
  • A complete blood analysis with a careful morphologic examination of peripheral blood and bone morrow smears completed by cytochemical reaction will help to classify the most acute myeloid leukaemia (AML).
  • Actually, the study of other cytogenetis and immunophenotypic markers are now necessary to confirm diagnosis.
  • The morphologic conclusion was difficult in 12% cases.
  • In WHO classification, cytology is essential in diagnosis of LAM even if the karytype have an important prognostic value.
  • [MeSH-major] Leukemia, Myeloid / classification
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Chromosome Aberrations. Diagnosis, Differential. Female. Humans. Infant. Karyotyping. Leukemia, Erythroblastic, Acute / blood. Leukemia, Erythroblastic, Acute / diagnosis. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Myelomonocytic, Acute / blood. Leukemia, Myelomonocytic, Acute / diagnosis. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / blood. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / genetics. Male. Middle Aged. Retrospective Studies. Tunisia. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040877.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


78. Tsellou E, Troungos C, Moschovi M, Athanasiadou-Piperopoulou F, Polychronopoulou S, Kosmidis H, Kalmanti M, Hatzakis A, Dessypris N, Kalofoutis A, Petridou E: Hypermethylation of CpG islands in the promoter region of the p15INK4B gene in childhood acute leukaemia. Eur J Cancer; 2005 Mar;41(4):584-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of CpG islands in the promoter region of the p15INK4B gene in childhood acute leukaemia.
  • In the present study, we investigated the methylation status of the p151NK4B gene to clarify its role in the pathogenesis of childhood acute myeloid (AML) and acute lymphoblastic leukaemia (ALL).
  • The study included 23 cases of B-cell origin ALL, 13 cases of T-cell origin ALL, 32 cases of AML, and 10 apparently healthy controls.
  • Hypermethylation of the p15INK4B gene was more frequent in cases with T-cell origin ALL (46.2%), but similar among children with B-cell origin ALL (13.0%) and AML (18.8%).
  • Hypermethylation of p15INK4B may be involved in the pathogenesis of T-cell origin ALL, but not in that of AML or B-cell origin ALL.
  • [MeSH-major] CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737564.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


79. Guo XL, Pan L, Zhang XJ, Suo XH, Niu ZY, Zhang JY, Wang F, Dong ZR, Da W, Ohno R: Expression and mutation analysis of genes that encode the Myc antagonists Mad1, Mxi1 and Rox in acute leukaemia. Leuk Lymphoma; 2007 Jun;48(6):1200-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and mutation analysis of genes that encode the Myc antagonists Mad1, Mxi1 and Rox in acute leukaemia.
  • In an attempt to identify mutations in Mad1, Mxi1 and Rox genes in human haematological malignancies, we screened 10 haematopoietic cell lines, bone marrow mononuclear cells (BMMNC) from 26 patients with haematological malignancies and peripheral blood mononuclear cells (PBMNC) from 30 healthy volunteers, using reverse transcription-polymerase chain reaction, single strand conformation polymorphism analysis and sequencing.
  • Four polymorphisms were found in cell lines BMMNC and PBMNC: two in Mad1, one in Mxi1 and one in Rox.
  • Nine missense mutations were detected: two in Mad1 in patients, four in Mxi1 (three in patients and one in KG-1 cell line), and three in Rox in patients.
  • Among six patients with acute lymphoblastic leukaemia, two had Mxi1 mutations and another two had Rox mutations.
  • [MeSH-major] Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Cycle Proteins / genetics. DNA Mutational Analysis. Leukemia / genetics. Nuclear Proteins / genetics. Proto-Oncogene Proteins c-myc / antagonists & inhibitors. Repressor Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Amino Acid Sequence. Base Sequence. Bone Marrow Cells / metabolism. Cell Line, Tumor. Female. Gene Expression. HL-60 Cells. Humans. K562 Cells. Male. Middle Aged. Molecular Sequence Data. Sequence Homology, Amino Acid. U937 Cells

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577784.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cell Cycle Proteins; 0 / MAD1L1 protein, human; 0 / MNT protein, human; 0 / MXI1 protein, human; 0 / MYC protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


80. Nollet S, Berger E, Deconinck E, Baldauf E, Rumbach L: [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone]. Rev Neurol (Paris); 2006 Feb;162(2):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].
  • [Transliterated title] Leucémies aiguës chez deux patients atteints de sclérose en plaques et traités par mitoxantrone.
  • Since 1998, eight cases of acute leukemia (AL) have been described.
  • In spite of a very low total dose (58.32 mg), she developed promyelocytic AL.
  • DISCUSSION: All the reported cases of AL occurring after Mx respond to the criteria of leukemia induced by anti-topoisomerases II.
  • Epidemiological data and those from animal experiments suggest that Mx has direct role in the occurrence of leukemia.
  • CONCLUSION: It must be remembered that even if the risk of Mx-induced leukemia is low, blood cell counts must be closely monitored for at least five years after the last injection of this treatment.
  • [MeSH-major] Analgesics / adverse effects. Leukemia / etiology. Mitoxantrone / adverse effects. Multiple Sclerosis / complications. Multiple Sclerosis / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Blood Cell Count. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol (Paris). 2006 Feb;162(2):157-9 [16518255.001]
  • (PMID = 16518259.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Analgesics; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


81. Koenigsmann M, Koehler M, Franke A, Frommer J: Acute leukaemia in adults: researching the patient's perspective. Leukemia; 2006 Feb;20(2):206-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukaemia in adults: researching the patient's perspective.
  • [MeSH-major] Leukemia / psychology. Physician-Patient Relations
  • [MeSH-minor] Acute Disease. Adaptation, Psychological. Adult. Anxiety / etiology. Depression / etiology. Humans. Quality of Life. Stress, Psychological / etiology


82. Shi M, Cui F, Li B, Li SY, Ma HJ: Mixed phenotype acute leukaemia with giant inclusions. Br J Haematol; 2010 Apr;149(1):2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed phenotype acute leukaemia with giant inclusions.
  • [MeSH-major] Inclusion Bodies / ultrastructure. Leukemia, Biphenotypic, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20015299.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. van Delft FW, Bellotti T, Luo Z, Jones LK, Patel N, Yiannikouris O, Hill AS, Hubank M, Kempski H, Fletcher D, Chaplin T, Foot N, Young BD, Hann IM, Gammerman A, Saha V: Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br J Haematol; 2005 Jul;130(1):26-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia.
  • We have prospectively analysed and correlated the gene expression profiles of children presenting with acute leukaemia to the Royal London and Great Ormond Street Hospitals with morphological diagnosis, immunophenotype and karyotype.
  • Total RNA extracted from freshly sorted blast cells was obtained from 84 lymphoblastic [acute lymphoblastic leukaemia (ALL)], 20 myeloid [acute myeloid leukaemia (AML)] and three unclassified acute leukaemias and hybridised to the high density Affymetrix U133A oligonucleotide array.
  • A novel 50-gene set accurately identified all patients with ALL and AML and predicted for a diagnosis of AML in three patients with unclassified acute leukaemia.
  • A unique gene set was derived for each of eight subtypes of acute leukaemia within our data set.
  • Our analyses demonstrate that not only is microarray analysis the single most effective tool for the diagnosis of acute leukaemias of childhood but it has the ability to identify unique biological pathways.
  • To further evaluate its prognostic value it needs to be incorporated into the routine diagnostic analysis for large-scale clinical trials in childhood acute leukaemias.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 21. Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Analysis of Variance. Child. Chromosome Banding. Core Binding Factor Alpha 2 Subunit. DNA-Binding Proteins / genetics. Diagnosis, Differential. Gene Rearrangement. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping. Leukemia / genetics. Leukemia, Myeloid / diagnosis. Leukemia, Myeloid / genetics. Nuclear Proteins / genetics. Ploidies. Principal Component Analysis. Prospective Studies. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-ets. Repressor Proteins / genetics. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Telomeric Repeat Binding Protein 2 / genetics. Transcription Factors / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982341.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 0 / Telomeric Repeat Binding Protein 2; 0 / Transcription Factors
  •  go-up   go-down


84. Ye Z, Song H: Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis. Eur J Cancer; 2005 May;41(7):980-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis.
  • Glutathione s-transferase (GST) polymorphisms (GSTM1, GSTP1 and GSTT1) have been considered as risk factors for developing acute leukaemia in a number of studies; however the overall results of such studies are inconsistent.
  • To investigate a putative association of GST polymorphisms with the risk of acute leukaemia, we performed a systematic review and meta-analysis of 30 published case-control studies.
  • The pooled OR of acute leukaemia risks associated with GSTM1 null genotype, GSTP1 Val105 allele and GSTT1 null genotype were 1.22 (95% confidence interval (CI) 1.07-1.38), 1.07 (95% CI 1.00-1.13) and 1.19 (95% CI 1.00-1.41), respectively.
  • Significantly increased risk of acute lymphoblastic leukaemia associated with GSTM1 and GSTT1 null genotypes was observed.
  • Our results suggest that GSTM1 and GSTT1, but not GSTP1 polymorphisms, appear to be associated with a modest increase in the risk of acute lymphoblastic leukaemia.
  • [MeSH-major] Glutathione Transferase / genetics. Isoenzymes / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Genotype. Glutathione S-Transferase pi. Humans. Odds Ratio. Risk Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862746.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  • [Number-of-references] 40
  •  go-up   go-down


85. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE, Center for International Blood and Marrow Transplant Research, Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation), National Cord Blood Program of the New York Blood Center: Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol; 2010 Jul;11(7):653-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.
  • We aimed to determine the optimal role of UCB grafts in transplantation for adults with acute leukaemia, and to establish whether current graft-selection practices are appropriate.
  • METHODS: We used Cox regression to retrospectively compare leukaemia-free survival and other outcomes for UCB, PBPC, and bone marrow transplantation in patients aged 16 years or over who underwent a transplant for acute leukaemia.
  • FINDINGS: Leukaemia-free survival in patients after UCB transplantation was comparable with that after 8/8 and 7/8 allele-matched PBPC or bone-marrow transplantation.
  • Grades 2-4 acute and chronic graft-versus-host disease (GvHD) were lower in UCB recipients compared with allele-matched PBPC (HR 0.57, 95% 0.42-0.77; p=0.002 and HR 0.38, 0.27-0.53; p=0.003, respectively), while the incidence of chronic, but not acute GvHD, was lower after UCB than after 8/8 allele-matched bone-marrow transplantation (HR 0.63, 0.44-0.90; p=0.01).
  • INTERPRETATION: These data support the use of UCB for adults with acute leukaemia when there is no HLA-matched unrelated adult donor available, and when a transplant is needed urgently.


86. You Y, Li QB, Chen ZC, Li WM, Xia LH, Zhou H, Zou P: Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation. Chin Med J (Engl); 2008 Sep 20;121(18):1770-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
  • BACKGROUND: Relapse remains an obstacle to successful allogeneic haematopoietic stem cell transplantation (allo-HSCT) for patients with acute leukaemia and no standard treatment is available.
  • We assessed fludarabine and cytarabine with transfusion of donor haematopoietic stem cell in treating the relapse of acute leukaemia after allo-HSCT.
  • METHODS: Seven patients, median age 34 years, with relapse of acute leukaemia after allo-HSCT received combination chemotherapy of fludarabine with cytarabine for 5 days.
  • Five patients suffered from acute myeloid leukaemia (2 refractory) and 2 refractory acute lymphoblastic leukaemia.
  • DNA sequence analysis at day 30 after treatment identified all as full donor chimera type.
  • Graft versus host disease occurred in 2 patients (acute) and 3 (chronic).
  • The other patients died of leukaemia related deaths.
  • Three patients with chronic graft versus host disease who had received donor peripheral blood stem cells reinfusion have survived for 375 days, 232 days and 195 days, respectively.
  • CONCLUSIONS: Fludarabine with cytarabine plus the donor haematopoietic stem cell should be considered as an effective therapeutic regimen for relapse of acute leukaemia after allo-HSCT.
  • The disease free state of patients may increase, though with high risk of secondary fungal infection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080355.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


87. Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC: Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol; 2010 Apr;149(2):263-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant.
  • Cases with an underlying diagnosis of acute leukaemia or following stem cell transplantation were included in a case control study.
  • Controls included all other children with acute leukaemia or stem cell transplant in the corresponding time period.
  • Variables collected included demographics, underlying disease risk and status, organ impairment, admission to intensive care unit, fungal infection details and certain transplant variables.
  • The incidence of invasive fungal infection was 21% in acute lymphoblastic leukaemia, 15% in acute myeloid leukaemia and 25% following stem cell transplantation.
  • Sixty per cent were neutropenic at diagnosis and 39% had concomitant bacteremia.
  • High risk acute lymphoblastic leukaemia, relapsed disease, intensive care admission and graft-versus-host disease were significantly associated with development of invasive fungal infection on multivariate analysis.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia / epidemiology. Mycoses / epidemiology. Opportunistic Infections / epidemiology
  • [MeSH-minor] Acute Disease. Adolescent. Case-Control Studies. Child. Child, Preschool. Cross Infection / complications. Cross Infection / epidemiology. Cross Infection / immunology. Graft vs Host Disease / complications. Graft vs Host Disease / epidemiology. Humans. Immunocompromised Host. Infant. Infant, Newborn. New South Wales / epidemiology. Risk Factors

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096013.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


88. Fanci R, Corti G, Bartoloni A, Tortoli E, Mariottini A, Pecile P: Unusual Methylobacterium fujisawaense Infection in a Patient with Acute Leukaemia Undergoing Hematopoietic Stem Cell Transplantation: First Case Report. Case Rep Med; 2010;2010:313514
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual Methylobacterium fujisawaense Infection in a Patient with Acute Leukaemia Undergoing Hematopoietic Stem Cell Transplantation: First Case Report.
  • Microorganisms of the genus Methylobacterium are facultative methylotrophic, gram-negative rods that are ubiquitous in nature and rarely cause human disease, mostly in subjects with preexisting causes of immune depression.
  • Here we describe a case of M. fujisawaense infection in a relapsed acute leukaemia undergoing unrelated allogeneic hematopoietic stem cell transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbiol Immunol. 2006;50(1):11-7 [16428868.001]
  • [Cites] Int J Syst Evol Microbiol. 2005 Jan;55(Pt 1):281-7 [15653888.001]
  • [Cites] Clin Infect Dis. 2000 Jun;30(6):936-8 [10880304.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Aug;36(8):1635-8 [1416844.001]
  • [Cites] J Clin Microbiol. 2001 May;39(5):2037-8 [11388170.001]
  • [Cites] Pediatr Infect Dis J. 1997 Oct;16(10):1007-8 [9380457.001]
  • (PMID = 20396386.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2852599
  •  go-up   go-down


89. Uggla B, Tina E, Nahi H, Paul C, Höglund M, Sirsjö A, Tidefelt U: Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. Int J Oncol; 2007 Jul;31(1):153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
  • The objective of this study was to correlate the expression of topoisomerase (topo) IIalpha to in vitro drug sensitivity and to the clinical outcome in patients with acute leukaemia.
  • In both groups, chemosensitivity testing by a bioluminescence ATP assay was performed to a variable extent for both topo IIalpha poisons and non-topo IIalpha targeting drugs.
  • Cell samples from patients with a high (>median value) percentage of topo IIalpha-positive cells were significantly more sensitive to the topo IIalpha active drugs etoposide and daunorubicin, and showed a borderline value for idarubicin (p=0.08), while there was no difference for non-topo IIalpha targeting drugs.
  • We conclude that expression of topo IIalpha, determined as percentage of topo IIalpha-positive cells, in leukaemic cells correlates to chemosensitivity in vitro against topoisomerase poisons but that it does not predict clinical outcome in acute leukaemia.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Drug Resistance, Neoplasm. Leukemia, Myeloid / enzymology. Leukemia, Myeloid / mortality
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Blood Cells / drug effects. Blood Cells / enzymology. Bone Marrow Cells / drug effects. Bone Marrow Cells / enzymology. Cell Survival. Daunorubicin. Etoposide / pharmacology. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / analysis. RNA, Messenger / metabolism

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549416.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 6PLQ3CP4P3 / Etoposide; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


90. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, Loberiza FR, Champlin RE, Klein JP, Horowitz MM, Wagner JE: Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet; 2007 Jun 9;369(9577):1947-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.
  • Our aim was to assess leukaemia-free survival after transplantations of these alternatives compared with present HLA-matching practices, and to assess the relative effect of cell dose and HLA match, and their potential interaction on leukaemia-free survival after cord-blood transplantation.
  • METHODS: Outcomes of 503 children (<16 years) with acute leukaemia and transplanted with umbilical cord blood were compared with outcomes of 282 bone-marrow recipients.
  • The primary endpoint was 5-year leukaemia-free survival.
  • FINDINGS: In comparison with allele-matched bone-marrow transplants, 5-year leukaemia-free survival was similar to that after transplants of umbilical cord blood mismatched for either one or two antigens and possibly higher after transplants of HLA-matched umbilical cord blood.
  • Transplant-related mortality rates were higher after transplants of two-antigen HLA-mismatched umbilical cord blood (relative risk 2.31, p=0.0003) and possibly after one-antigen HLA-mismatched low-cell-dose umbilical-cord-blood transplants (1.88, p=0.0455).
  • INTERPRETATION: These data support the use of HLA-matched and one- or two-antigen HLA-mismatched umbilical cord blood in children with acute leukaemia who need transplantation.
  • Because better HLA matching and higher cell doses significantly decrease the risk of transplant-related mortality after umbilical-cord-blood transplantation, greater investment in large-scale banking is needed to increase HLA diversity.


91. Bernard F, Bordigoni P, Simeoni MC, Barlogis V, Contet A, Loundou A, Thuret I, Leheup B, Chambost H, Play B, Auquier P, Michel G: Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI. Bone Marrow Transplant; 2009 Apr;43(8):637-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.
  • We compared the impact of a conditioning regimen with BU (n=16) or fractionated TBI (n=42) on height growth during adolescence and final height (FH), in 58 adults transplanted for acute leukaemia before adolescence (younger than 9 for girls and 11 for boys, and prepubertal).
  • The influence of the conditioning regimen was assessed using multiple linear regression and adjusting for gender, central nervous system irradiation, age and leukaemia status at transplant and type of transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / physiopathology. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011662.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Willemze AJ, Geskus RB, Noordijk EM, Kal HB, Egeler RM, Vossen JM: HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant; 2007 Aug;40(4):319-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI.
  • To examine relapse, survival and transplant-related complications in relationship to disease- and pre-treatment-related characteristics, we evaluated 132 children, who consecutively received an allogeneic HLA-identical SCT for acute leukaemia in our centre: ALL in first remission (n=24), ALL in second remission (n=53) and AML in first remission (n=55).
  • The incidence of acute GVHD was 17%; 6% was grades II-IV.
  • AML patients with acute GVHD got no relapse (P=0.02); this was not the case in ALL patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Whole-Body Irradiation / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Graft Survival. Graft vs Host Disease. Humans. Infant. Kaplan-Meier Estimate. Male. Recurrence. Retrospective Studies. Transplantation Conditioning / methods. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572715.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Johansson E, Engervall P, Björvell H, Hast R, Björkholm M: Patients' perceptions of having a central venous catheter or a totally implantable subcutaneous port system-results from a randomised study in acute leukaemia. Support Care Cancer; 2009 Feb;17(2):137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients' perceptions of having a central venous catheter or a totally implantable subcutaneous port system-results from a randomised study in acute leukaemia.
  • GOALS OF WORK: The selection process of type of central venous access device (CVAD) in patients with acute leukaemia (AL) is generally based on appropriate catheter capacity/function and risk of complications in relation to the planned length of therapy.
  • Advantages and disadvantages of the CVAD from the patient's perspective should also be important parts in the selection of type of device.
  • Perceptions on having a CVAD were thus analysed in a series of adult patients with AL included in a prospective randomised study evaluating the use of a double lumen totally implantable subcutaneous port system (PORT) or a double lumen central venous catheter (CVC) regarding survival time and complication rate.
  • [MeSH-major] Catheterization, Central Venous. Catheters, Indwelling. Leukemia / drug therapy. Patient Satisfaction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449573.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


94. Halliday C, Hoile R, Sorrell T, James G, Yadav S, Shaw P, Bleakley M, Bradstock K, Chen S: Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. Br J Haematol; 2006 Feb;132(4):478-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia.
  • Guidelines for the use of polymerase chain reaction (PCR)-based assays to aid the diagnosis of invasive aspergillosis (IA) in high-risk haematology patients have not been formulated.
  • We prospectively evaluated a nested PCR assay to detect Aspergillus in blood during 95 febrile neutropenic episodes, in patients with haematological malignancy and haematopoietic stem cell transplant (HSCT) recipients.
  • Overall, PCR positivity preceded standard diagnosis by a mean of 14 d and the median time between positive results was shorter than that in other categories of IA.
  • All 13 episodes occurred in the setting of allogeneic HSCT recipients and acute leukaemia.
  • [MeSH-major] Aspergillosis / diagnosis. Aspergillus / genetics. DNA, Fungal / blood. Hematopoietic Stem Cell Transplantation. Leukemia / microbiology. Neutropenia / microbiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antifungal Agents / therapeutic use. Female. Fluconazole / therapeutic use. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods. Sensitivity and Specificity


95. Kobayashi K, Kami M, Murashige N, Kusumi E, Kishi Y, Hamaki T, Hori A, Matsumura T, Yuji K, Masuo S, Mori S, Miyakoshi S, Tanosaki R, Mitamura T, Takaue Y, Taniguchi S, Tokyo SCT Consortium Institution: Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. Br J Haematol; 2005 Jun;129(6):795-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors.
  • The characteristics of relapse following reduced-intensity stem-cell transplantation (RIST) remain to be clarified.
  • We reviewed the medical records of 19 patients with acute leukaemia [acute myeloid leukaemia (AML), 16; acute lymphoblastic leukaemia (ALL), 3] who relapsed after RIST from related donors using purine-analogue-based regimens.
  • Causes of death in 15 patients included progressive disease (n = 7), graft-versus-host disease (n = 5) and infections (n = 3).
  • Cumulative incidences of relapse-related and non-relapse-related deaths at 2 years after relapse were 37% and 32% respectively.
  • Two prognostic factors were identified on univariate analysis: age [P = 0.017; hazard ratio (HR), 1.16; 95% confidence interval (CI), 1.03-1.32], and ALL as underlying disease (P = 0.011; HR, 10.4; 95% CI, 1.73-62.4).
  • Some AML patients who relapse after RIST achieve durable remission with allogeneic immunotherapy-based interventions; however they carry a significant risk of non-relapse mortality.
  • [MeSH-major] HLA Antigens / analysis. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Cause of Death. Female. Graft vs Host Disease / etiology. Histocompatibility Testing. Humans. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953007.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


96. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, Chen YF: Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol Assess; 2010 Dec;14(54):iii-iv, ix-xi, 1-141
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
  • BACKGROUND: Acute leukaemia is a group of rapidly progressing cancers of bone marrow and blood classified as either acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).
  • Haemopoietic stem cell transplantation (SCT) has developed as an adjunct to or replacement for conventional chemotherapy with the aim of improving survival and quality of life.
  • OBJECTIVES: A systematic overview of the best available evidence on the clinical effectiveness and cost-effectiveness of SCT in the treatment of acute leukaemia.
  • DATA SOURCES: Clinical effectiveness: electronic databases, including MEDLINE, EMBASE and the Cochrane Library, were searched from inception to December 2008 to identify published systematic reviews and meta-analyses.
  • Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery


97. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A: Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol; 2008 Sep;9(9):831-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.
  • The aim of this phase I/II study was to establish the safety and efficacy of a new administration route (intrabone) for cord-blood cells, measured by the donor-derived neutrophil and platelet engraftment.
  • METHODS: Adult patients with acute leukaemia, for whom an unrelated stem-cell transplantation was indicated and no suitable unrelated human leucocyte antigen (HLA)-matched donor had been identified, were included in the study and underwent a cord-blood transplant in San Martino Hospital, Genoa, Italy.
  • Eight patients were in first complete remission, ten in second complete remission, and 14 had advanced-stage, refractory disease.
  • Median transplanted cell dose was 2.6 x 10(7)/kg (range 1.4-4.2).
  • Secondary endpoints included the incidence of acute graft-versus-host disease, relapse, and overall survival.
  • FINDINGS: Between March 31, 2006, and Jan 25, 2008, 32 consecutive patients with acute myeloid leukaemia (n=20) or acute lymphoblastic leukaemia (n=12) underwent a cord-blood transplant (median age 36 years [range 18-66]).
  • Four patients with advanced-stage disease died within 12 days of the procedure.
  • No patient developed grade III-IV acute graft-versus-host disease.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


98. Gupta S, Bonilla M, Fuentes SL, Caniza M, Howard SC, Barr R, Greenberg ML, Ribeiro R, Sung L: Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. Br J Cancer; 2009 Apr 7;100(7):1026-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador.
  • Survival rates among children with leukaemia in low-income countries are lower than those in high-income countries.
  • We examined the demographics, treatment, and outcomes of paediatric patients in El Salvador with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML) to determine the incidence, causes, and risk factors for TRM.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2001 Mar;15(3):348-54 [11237056.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):50-8 [16173962.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):266-8 [11920793.001]
  • [Cites] Hematol Oncol. 2003 Mar;21(1):1-9 [12605417.001]
  • [Cites] Br J Haematol. 2003 Jul;122(2):217-25 [12846889.001]
  • [Cites] Lancet. 2003 Aug 30;362(9385):706-8 [12957095.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):677-87 [14770421.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] JAMA. 2004 May 26;291(20):2471-5 [15161898.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1677-84 [15378506.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4384-93 [15514380.001]
  • [Cites] Arch Dis Child. 1996 Feb;74(2):101-7 [8660070.001]
  • [Cites] Med Pediatr Oncol. 1997 Jan;28(1):48-53 [8950336.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):167-76 [10093685.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):436-44 [10460604.001]
  • [Cites] Pediatr Blood Cancer. 2005 Apr;44(4):303-4 [15486952.001]
  • [Cites] Leukemia. 2005 Apr;19(4):537-44 [15690069.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2117-24 [16107894.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2101-16 [16136167.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4499-506 [16983120.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):23-7 [16862536.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3532-9 [17660380.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):499-501; discussion 517 [18064663.001]
  • [Cites] Pediatrics. 2002 Jan;109(1):45-60 [11773541.001]
  • (PMID = 19293804.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2669993
  •  go-up   go-down


99. Aversa F: Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant; 2008 Mar;41(5):473-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.
  • The graft may be a megadose of extensively T cell-depleted or unmanipulated progenitor cells.
  • Improvements will come with successful implementation of strategies to accelerate and strengthen post transplant immune reconstitution as well as transplantation of patients in early stage disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Disease-Free Survival. Europe. Graft vs Host Disease / prevention & control. Haploidy. Humans. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Transplantation, Homologous / adverse effects. Transplantation, Homologous / methods. United States


100. Gottfredsson M, Steingrímsdóttir H: Disseminated invasive aspergillosis in a patient with acute leukaemia. Acta Biomed; 2006;77 Suppl 2:10-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated invasive aspergillosis in a patient with acute leukaemia.
  • A 46-year-old previously healthy woman was diagnosed with acute lymphoblastic leukaemia.
  • Bronchoscopy was performed and treatment was administered with liposomal amphotericin B (L-AmB, AmBisome) for two days, but was complicated by acute renal failure.
  • The patient died one week following the diagnosis of aspergillosis.
  • [MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Aspergillosis / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bacteremia / complications. Bacteremia / drug therapy. Chlamydophila Infections / complications. Chlamydophila Infections / drug therapy. Chlamydophila pneumoniae. Doxorubicin / administration & dosage. Drug Resistance, Multiple, Fungal. Drug Therapy, Combination. Echinocandins. Fatal Outcome. Female. Humans. Immunocompromised Host. Liposomes. Lung Diseases, Fungal / complications. Lung Diseases, Fungal / drug therapy. Medical Futility. Methotrexate / administration & dosage. Middle Aged. Neuroaspergillosis / drug therapy. Neuroaspergillosis / etiology. Peptides, Cyclic / administration & dosage. Peptides, Cyclic / therapeutic use. Pneumonia, Bacterial / complications. Pyrimidines / therapeutic use. Streptococcal Infections / complications. Streptococcal Infections / drug therapy. Triazoles / therapeutic use. Vincristine / administration & dosage. Voriconazole

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Acta Biomed. 2006;77 Suppl 4:following 33
  • (PMID = 16918060.001).
  • [ISSN] 0392-4203
  • [Journal-full-title] Acta bio-medica : Atenei Parmensis
  • [ISO-abbreviation] Acta Biomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Echinocandins; 0 / Liposomes; 0 / Peptides, Cyclic; 0 / Pyrimidines; 0 / Triazoles; 0 / liposomal amphotericin B; 5J49Q6B70F / Vincristine; 7XU7A7DROE / Amphotericin B; 80168379AG / Doxorubicin; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement